

Don't settle for just a supplier. Find a custom manufacturing partner.

Your specifications. Your format.
Our scientists waiting to help.



Let's **TALK**
CUSTOM



Selecting a supplier for your clinical/diagnostic products can be a challenge—especially a supplier who can adapt to your specific needs. Don't settle for just a supplier. Instead, partner with Promega and work with a custom manufacturer willing to provide you with the scientific expertise, ongoing technical support and quality standards that support your success.



Learn more with our free webinar:
promega.com/CustomWebinar

SPECIAL ARTICLE

Large scale multifactorial likelihood quantitative analysis of *BRCA1* and *BRCA2* variants: An ENIGMA resource to support clinical variant classification

Michael T. Parsons¹  | Emma Tudini¹ | Hongyan Li² | Eric Hahnen^{3,4} | Barbara Wappenschmidt^{3,4} | Lidia Feliubadaló⁵ | Cora M. Aalfs⁶ | Simona Agata⁷ | Kristiina Aittomäki⁸ | Elisa Alducci⁷ | María Concepción Alonso-Cerezo⁹ | Norbert Arnold^{10,11} | Bernd Auber¹² | Rachel Austin¹³ | Jacopo Azzollini¹⁴ | Judith Balmaña^{15,16} | Elena Barbieri¹⁷ | Claus R. Bartram¹⁸ | Ana Blanco¹⁹ | Britta Blümcke^{3,4} | Sandra Bonache²⁰ | Bernardo Bonanni²¹ | Åke Borg²² | Beatrice Bortesi²³ | Joan Brunet⁵ | Carla Bruzzone²⁴ | Karolin Bucksch²⁵ | Giulia Cagnoli¹⁴ | Trinidad Caldés²⁶ | Almuth Caliebe²⁷ | Maria A. Caligo²⁸ | Mariarosaria Calvello²¹ | Gabriele L. Capone²⁹ | Sandrine M. Caputo^{30,31} | Ileana Carnevali³² | Estela Carrasco¹⁵ | Virginie Caux-Moncoutier³⁰ | Pietro Cavalli³³ | Giulia Cini³⁴ | Edward M. Clarke¹ | Paola Concolino³⁵ | Elisa J. Cops³⁶ | Laura Cortesi¹⁷ | Fergus J. Couch³⁷ | Esther Darder⁵ | Miguel de la Hoya²⁶  | Michael Dean³⁸ | Irmgard Debatin³⁹ | Jesús Del Valle⁵ | Capucine Delnatte⁴⁰ | Nicolas Derive^{30,31} | Orland Diez^{20,41}  | Nina Ditsch⁴² | Susan M. Domchek⁴³ | Véronique Dutrannoy⁴⁴ | Diana M. Eccles⁴⁵  | Hans Ehrencrona^{46,47} | Ute Enders²⁵ | D. Gareth Evans^{48,49} | Chantal Farra⁵⁰ | Ulrike Faust⁵¹ | Ute Felbor⁵² | Irene Feroce²¹ | Miriam Fine⁵³ | William D. Foulkes⁵⁴ | Henrique C.R. Galvao⁵⁵ | Gaetana Gambino²⁸ | Andrea Gehrig⁵⁶ | Francesca Gensini²⁹ | Anne-Marie Gerdes⁵⁷ | Aldo Germani⁵⁸ | Jutta Giesecke^{3,4} | Viviana Gismondi²⁴ | Carolina Gómez⁵ | Encarna B. Gómez García⁵⁹ | Sara González⁵ | Elia Grau⁵ | Sabine Grill⁶⁰ | Eva Gross⁴² | Aliana Guerrieri-Gonzaga²¹ | Marine Guillaud-Bataille⁶¹ | Sara Gutiérrez-Enríquez²⁰  | Thomas Haaf⁵⁶ | Karl Hackmann⁶² | Thomas V.O. Hansen⁵⁷ | Marion Harris⁶³ | Jan Hauke^{3,4} | Tilman Heinrich⁵¹ | Heide Hellebrand⁶⁰ | Karen N. Herold⁶⁴ | Ellen Honisch⁶⁵ | Judit Horvath⁶⁶ | Claude Houdayer⁶⁷ | Verena Hübbel^{3,4} | Silvia Iglesias⁵ | Angel Izquierdo⁵ |

*David Goldgar and Amanda Spurdle should be considered joint senior authors.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors Human Mutation Published by Wiley Periodicals, Inc.

Paul A. James^{36,68} | Linda A.M. Janssen⁶⁹ | Udo Jeschke⁴² | Silke Kaulfuß⁷⁰ |
Katharina Keupp^{3,4} | Marion Kiechle⁶⁰ | Alexandra Kölbl⁴² | Sophie Krieger^{71,72,73} |
Torben A. Kruse⁷⁴ | Anders Kvist²² | Fiona Laloo⁴⁹ | Mirjam Larsen^{3,4} |
Vanessa L. Lattimore⁷⁵ | Charlotte Lautrup^{76,77} | Susanne Ledig⁶⁶ | Elena Leinert⁷⁸ |
Alexandra L. Lewis⁷⁹ | Joanna Lim⁸⁰ | Markus Loeffler²⁵ | Adrià López-Fernández¹⁵ |
Emanuela Lucci-Cordisco⁸¹ | Nicolai Maass¹⁰ | Siranoush Manoukian¹⁴ |
Monica Marabelli²¹ | Laura Matricardi⁷ | Alfons Meindl⁴² | Rodrigo D. Michelli⁵⁵ |
Setareh Moghadasi⁶⁹ | Alejandro Moles-Fernández²⁰ | Marco Montagna⁷ |
Gemma Montalban²⁰ | Alvaro N. Monteiro⁸² | Eva Montes⁵ | Luigi Mori⁸³ |
Lidia Moserle⁷ | Clemens R. Müller⁵⁶ | Christoph Mundhenke¹⁰ | Nadia Naldi²³ |
Katherine L. Nathanson⁴³ | Matilde Navarro⁵ | Heli Nevanlinna⁸⁴ |
Cassandra B. Nichols⁸⁵ | Dieter Niederacher⁶⁵ | Henriette R. Nielsen⁷⁴ |
Kai-ren Ong⁸⁶ | Nicholas Pachter^{85,87} | Edenir I. Palmero^{88,89} | Laura Papi²⁹ |
Inge Sokilde Pedersen^{77,90,91} | Bernard Peissel¹⁴ | Pedro Perez-Segura²⁶ |
Katharina Pfeifer⁶⁰ | Marta Pineda⁵ | Esther Pohl-Rescigno^{3,4} | Nicola K. Poplawski^{53,92} |
Berardino Porfirio²⁹ | Anne S. Quante⁶⁰ | Juliane Ramser⁶⁰ | Rui M. Reis^{88,93,94} |
Françoise Revillion⁹⁵ | Kerstin Rhiem^{3,4} | Barbara Riboli³³ | Julia Ritter⁴⁴ |
Daniela Rivera²⁴ | Paula Rofes⁵ | Andreas Rump⁶² | Monica Salinas⁵ |
Ana María Sánchez de Abajo⁹⁶ | Gunnar Schmidt¹² | Ulrike Schoenwiese²⁵ |
Jochen Seggewiß⁶⁶ | Ares Solanes⁵ | Doris Steinemann¹² | Mathias Stiller⁹⁷ |
Dominique Stoppa-Lyonnet^{30,98,99} | Kelly J. Sullivan¹⁰⁰ | Rachel Susman¹³  |
Christian Sutter¹⁸ | Sean V. Tavtigian^{101,102}  | Soo H. Teo^{80,103} | Alex Teulé⁵ |
Mads Thomassen⁷⁴ | Maria Grazia Tibiletti³² | Marc Tischkowitz¹⁰⁴ | Silvia Tognazzo⁷ |
Amanda E. Toland¹⁰⁵  | Eva Tornero⁵ | Therese Törngren²² | Sara Torres-Esquius¹⁵ |
Angela Toss¹⁷  | Alison H. Trainer^{36,106} | Katherine M. Tucker^{107,108} |
Christi J. van Asperen⁶⁹ | Marion T. van Mackelenbergh¹⁰ | Liliana Varesco²⁴ |
Gardenia Vargas-Parra⁵ | Raymonda Varon⁴⁴ | Ana Vega¹⁹  | Ángela Velasco⁵ |
Anne-Sophie Vesper⁶⁵ | Alessandra Viel³⁴ | Maaïke P. G. Vreeswijk¹⁰⁹  |
Sebastian A. Wagner¹¹⁰ | Anke Waha^{3,4} | Logan C. Walker⁷⁵ | Rhiannon J. Walters¹ |
Shan Wang-Gohrke⁷⁸ | Bernhard H. F. Weber¹¹¹ | Wilko Weichert¹¹² | Kerstin Wieland²⁵ |
Lisa Wiesmüller⁷⁸ | Isabell Witzel¹¹³ | Achim Wöckel¹¹⁴ | Emma R. Woodward^{48,49}  |
Silke Zachariae²⁵ | Valentina Zampiga¹¹⁵ | Christine Zeder-Göös⁴² |
KConFab Investigators^{68,116} | Conxi Lázaro⁵ | Arcangela De Nicolo¹¹⁷ | Paolo Radice¹¹⁸  |
Christoph Engel²⁵ | Rita K. Schmutzler^{3,4} | David E. Goldgar^{119*} | Amanda B. Spurdle^{1*} 

- ¹Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
- ²Cancer Control and Population Science, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
- ³Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- ⁴Center for Integrated Oncology (CIO), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- ⁵Hereditary Cancer Program, ONCOBELL-IDIBELL-IDIBGI-IGTP, Catalan Institute of Oncology, CIBERONC, Barcelona, Spain
- ⁶Department of Clinical Genetics, Amsterdam UMC, Amsterdam, The Netherlands
- ⁷Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV, IRCCS, Padua, Italy
- ⁸Department of Clinical Genetics, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
- ⁹Clinical Genetics, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria, Madrid, Spain
- ¹⁰Department of Gynaecology and Obstetrics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany
- ¹¹Institute of Clinical Molecular Biology, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany
- ¹²Institute of Human Genetics, Hannover Medical School, Hannover, Germany
- ¹³Genetic Health Queensland, Royal Brisbane and Women's Hospital, Brisbane, Australia
- ¹⁴Unit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
- ¹⁵High Risk and Cancer Prevention Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain
- ¹⁶Department of Medical Oncology, University Hospital of Vall d'Hebron, Barcelona, Spain
- ¹⁷Department of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy
- ¹⁸Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany
- ¹⁹Fundación Pública galega Medicina Xenómica-SERGAS, Grupo de Medicina Xenómica-USC, CIBERER, IDIS, Santiago de Compostela, Spain
- ²⁰Oncogenetics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
- ²¹Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, Milan, Italy
- ²²Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
- ²³Division of Oncology, University Hospital of Parma, Parma, Italy
- ²⁴Unit of Hereditary Cancer, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- ²⁵Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
- ²⁶Molecular Oncology Laboratory, CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain
- ²⁷Institute of Human Genetics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany
- ²⁸SOD Genetica Molecolare, University Hospital, Pisa, Italy
- ²⁹Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', Medical Genetics Unit, University of Florence, Florence, Italy
- ³⁰Service de Génétique, Institut Curie, Paris, France
- ³¹Paris Sciences Lettres Research University, Paris, France
- ³²UO Anatomia Patologica, Ospedale di Circolo ASST Settelaghi, Varese, Italy
- ³³Servizio di Genetica, ASST di Cremona, Cremona, Italy
- ³⁴Division of Functional Onco-genomics and Genetics, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy
- ³⁵Fondazione Policlinico Universitario A.Gemelli, IRCCS, Rome, Italy
- ³⁶Parkville Familial Cancer Centre, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia
- ³⁷Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
- ³⁸Laboratory of Translational Genomics, DCEG, National Cancer Institute, Gaithersburg, Maryland
- ³⁹Institute of Human Genetics, University Hospital Ulm, Ulm, Germany
- ⁴⁰Laboratoire de Genetique Moleculaire, CHU Nantes, Nantes, France
- ⁴¹Clinical and Molecular Genetics Area, University Hospital Vall d'Hebron, Barcelona, Spain
- ⁴²Department of Gynecology and Obstetrics, University of Munich, Munich, Germany
- ⁴³Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania
- ⁴⁴Institute of Medical and Human Genetics, Charité –Universitätsmedizin Berlin, Berlin, Germany
- ⁴⁵Faculty of Medicine, University of Southampton, Southampton, UK
- ⁴⁶Department of Clinical Genetics and Pathology, Laboratory Medicine, Office for Medical Services - Region Skåne, Lund, Sweden
- ⁴⁷Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden
- ⁴⁸Genomic Medicine, Division of Evolution and Genomic Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester Universities Foundation Trust, St. Mary's Hospital, Manchester, UK
- ⁴⁹Genomic Medicine, North West Genomics hub, Manchester Academic Health Science Centre, Manchester Universities Foundation Trust, St. Mary's Hospital, Manchester, UK
- ⁵⁰Medical Genetics, American University of Beirut Medical Center, Beirut, Lebanon

- ⁵¹Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany
- ⁵²Institute of Human Genetics, University Medicine Greifswald, Greifswald, Germany
- ⁵³Adult Genetics Unit, Royal Adelaide Hospital, Adelaide, Australia
- ⁵⁴Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill University, Montréal, QC, Canada
- ⁵⁵Oncogenetics Department, Barretos Cancer Hospital, São Paulo, Brazil
- ⁵⁶Department of Human Genetics, University of Würzburg, Würzburg, Germany
- ⁵⁷Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
- ⁵⁸Department of Clinical and Molecular Medicine, Sant'Andrea University Hospital, Sapienza University, Rome, Italy
- ⁵⁹Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands
- ⁶⁰Division of Gynaecology and Obstetrics, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany
- ⁶¹Departement de Biopathologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- ⁶²Institute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany
- ⁶³Familial Cancer Centre, Monash Health, Clayton, Australia
- ⁶⁴The City of Hope, Duarte, California
- ⁶⁵Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
- ⁶⁶Institute of Human Genetics, University of Münster, Münster, Germany
- ⁶⁷Department of Genetics, F76000 and Normandy University, UNIROUEN, Inserm U1245, Normandy Centre for Genomic and Personalized Medicine, Rouen University Hospital, Rouen, France
- ⁶⁸Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia
- ⁶⁹Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
- ⁷⁰Institute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany
- ⁷¹Laboratoire de Biologie Clinique et Oncologique, Centre Francois Baclesse, Caen, France
- ⁷²Genomics and Personalized Medicine in Cancer and Neurological Disorders, Normandy Centre for Genomic and Personalized Medicine, Rouen, France
- ⁷³Normandie Université, UNICAEN, Caen, France
- ⁷⁴Department of Clinical Genetics, Odense University Hospital, Odense C, Denmark
- ⁷⁵Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand
- ⁷⁶Department of Clinical Genetics, Aalborg University Hospital, Aalborg, Denmark
- ⁷⁷Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
- ⁷⁸Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany
- ⁷⁹Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
- ⁸⁰Breast Cancer Research Programme, Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia
- ⁸¹UOC Genetica Medica, Fondazione Policlinico Universitario A.Gemelli IRCCS and Istituto di Medicina Genomica, Università Cattolica del Sacro Cuore, Rome, Italy
- ⁸²Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida
- ⁸³Department of Clinical and Experimental Science, University of Brescia c/o 2nd Internal Medicine, Hospital of Brescia, Brescia, Italy
- ⁸⁴Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
- ⁸⁵Genetic Services of Western Australia, King Edward Memorial Hospital, Perth, Australia
- ⁸⁶West Midlands Regional Genetics Service, Birmingham Women's Hospital Healthcare NHS Trust, Birmingham, UK
- ⁸⁷Faculty of Health and Medical Sciences, University of Western Australia, Perth, Australia
- ⁸⁸Molecular Oncology Research Center, Barretos Cancer Hospital, São Paulo, Brazil
- ⁸⁹Barretos School of Health Sciences, Dr. Paulo Prata - FACISB, São Paulo, Brazil
- ⁹⁰Molecular Diagnostics, Aalborg University Hospital, Aalborg, Denmark
- ⁹¹Department of Clinical Medicine, Aalborg University, Aalborg, Denmark,
- ⁹²School of Paediatrics and Reproductive Health, University of Adelaide, Adelaide, Australia
- ⁹³Health Sciences School, University of Minho, Braga, Portugal
- ⁹⁴ICVS/3B's-PT Government Associate Laboratory, Braga, Portugal
- ⁹⁵Laboratoire d'Oncogenetique Moleculaire Humaine, Centre Oscar Lambret, Lille, France
- ⁹⁶Servicio de Análisis Clínicos y Bioquímica Clínica, Complejo Hospitalario, Universitario Insular Materno-Infantil de Gran Canaria, Las Palmas de Gran Canaria, Spain
- ⁹⁷Institute of Human Genetics, University Hospital Leipzig, Leipzig, Germany
- ⁹⁸Department of Tumour Biology, INSERM U830, Paris, France
- ⁹⁹Université Paris Descartes, Paris, France
- ¹⁰⁰Genetic Health Service NZ- Northern Hub, Auckland District Health Board, Auckland, New Zealand
- ¹⁰¹Department of Oncological Services, University of Utah School of Medicine, Salt Lake City, Utah

¹⁰²Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah

¹⁰³Department of Surgery, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia

¹⁰⁴Department of Medical Genetics, University of Cambridge, Cambridge, UK

¹⁰⁵Department of Cancer Biology and Genetics, The Ohio State University, Columbus, Ohio

¹⁰⁶Department of medicine, University of Melbourne, Melbourne, Victoria, Australia

¹⁰⁷Prince of Wales Clinical School, University of NSW, Sydney, New South Wales, Australia

¹⁰⁸Hereditary Cancer Clinic, Department of Medical Oncology, Prince of Wales Hospital, Randwick, New South Wales, Australia

¹⁰⁹Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands

¹¹⁰Department of Medicine, Hematology/Oncology, Goethe-University Frankfurt, Frankfurt, Germany

¹¹¹Institute of Human Genetics, University Regensburg, Regensburg, Germany

¹¹²Institute of Pathology, Technische Universität München, Munich, Germany

¹¹³Department of Gynecology, University Medical Center Hamburg, Hamburg, Germany

¹¹⁴Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg, Germany

¹¹⁵Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

¹¹⁶Research Department, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia

¹¹⁷Cancer Genomics Program, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy

¹¹⁸Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy

¹¹⁹Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah

Correspondence

Amanda B. Spurdle, Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Email: Amanda.Spurdle@qimrberghofer.edu.au

Funding information

Ohio State University Comprehensive Cancer Center; Barretos Cancer Hospital, Grant/Award Number: FINEP - CT-INFRA (02/2010); Breast Cancer Foundation of New Zealand; Canadian Institutes of Health Research, Grant/Award Number: PSR-SIIRI-701; Cancer Research UK, Grant/Award Numbers: C8197/A16565, C5047/A8384, C1281/A12014, C12292/A11174, C1287/A10710, C1287/A10118, C1287/A16563, C5047/A10692, C5047/A15007; Department of Defence, USA, Grant/Award Number: W81XWH-10-1-0341; Helsinki University Hospital Research fund; Scientific Foundation Asociación Española Contra el Cáncer; Leiden University Medical Centre, Grant/Award Number: Grant 30.925; Generalitat de Catalunya, Grant/Award Numbers: PERIS_MedPerCan, URDCat, 2017SGR1282, 2017SGR496; Royal Society of New Zealand; Cancer Council Victoria; Netherlands Organization for Scientific Research (NWO), Grant/Award Number: Grant 017.008.022; Breast Cancer Research Foundation; Cancer Foundation of Western Australia; EU H2020, Grant/Award Number: 634935; Fundación Mutua Madrileña; Seventh Framework Programme, Grant/Award Numbers: 634935, 223175, 633784; Cancer Council South Australia; Government of Galicia, Grant/Award Number: Consolidation and structuring program: IN607B; Cancer Council Tasmania; Italian Association of Cancer Research, Grant/Award Number: 15547; Queensland Cancer Fund; AstraZeneca; National Institute of Health

Abstract

The multifactorial likelihood analysis method has demonstrated utility for quantitative assessment of variant pathogenicity for multiple cancer syndrome genes. Independent data types currently incorporated in the model for assessing *BRCA1* and *BRCA2* variants include clinically calibrated prior probability of pathogenicity based on variant location and bioinformatic prediction of variant effect, co-segregation, family cancer history profile, co-occurrence with a pathogenic variant in the same gene, breast tumor pathology, and case-control information. Research and clinical data for multifactorial likelihood analysis were collated for 1,395 *BRCA1/2* predominantly intronic and missense variants, enabling classification based on posterior probability of pathogenicity for 734 variants: 447 variants were classified as (likely) benign, and 94 as (likely) pathogenic; and 248 classifications were new or considerably altered relative to ClinVar submissions. Classifications were compared with information not yet included in the likelihood model, and evidence strengths aligned to those recommended for ACMG/AMP classification codes. Altered mRNA splicing or function relative to known nonpathogenic variant controls were moderately to strongly predictive of variant pathogenicity. Variant absence in population datasets provided supporting evidence for variant pathogenicity. These findings have direct relevance for *BRCA1* and *BRCA2* variant evaluation, and justify the need for gene-specific calibration of evidence types used for variant classification.

KEYWORDS

BRCA1, *BRCA2*, classification, clinical, multifactorial, quantitative, uncertain significance, variant

(USA), Grant/Award Numbers: 1U19 CA148065-01, CA128978, CA192393, 1U19 CA148537, P50 CA1162091, CA116167, 1U19 CA148112; Newcastle University; Dutch Cancer Society KWF, Grant/Award Numbers: KWF/Pink Ribbon-11704, UL2012-5649; National Institute for Health Research, Grant/Award Number: Manchester Biomedical Research centre (IS-BRC-1215; National Council of Technological and Scientific Development (CNPq); Instituto de Salud Carlos III, Grant/Award Numbers: FIS PI15/00355, FIS PI13/01711, CIBERONC, FIS PI16/01218, PI16/00563; French National Institute of Cancer; National Breast Cancer Foundation; National Health and Medical Research Council, Grant/Award Numbers: ID1061778, ID1104808; Carlos III National Health; Centro de Investigación Biomédica en Red de Enfermedades Raras, Grant/Award Number: ACCI 2016: ER17P1AC7112/2018; Cancer Council NSW; Deutsche Krebshilfe, Grant/Award Numbers: (#110837, #70111850; Fondazione Pisa, Grant/Award Number: Grant "Clinical characterization of BRCA 1/2 Mis

1 | INTRODUCTION

BRCA1 and *BRCA2* variants resulting in abrogated function of the encoded proteins confer a high risk of breast and ovarian cancer (Antoniou et al., 2003; Kuchenbaecker et al., 2017), and have been reported to increase risk of several other cancer types (Breast Cancer Linkage C, 1999; Ford, Easton, Bishop, Narod, & Goldgar, 1994; Moran et al., 2012; Thompson, Easton, & Breast Cancer Linkage C, 2002). The cancer types commonly considered important for risk assessment are breast (female and male), ovarian, prostate, and pancreatic cancer, all of which are included in the BOADICEA model predicting risk of cancer for *BRCA1* and *BRCA2* pathogenic variant carriers (Antoniou et al., 2008). Identification of a pathogenic *BRCA1* or *BRCA2* variant is important clinical information that directs medical management of an individual, including strategies aimed at prevention (risk-reducing surgery or medication), early detection (presymptomatic screening), and more recently personalized treatment with PARP-inhibitors (Pilie, Tang, Mills, & Yap, 2019). Further, cascade testing of close relatives of a pathogenic variant carrier is an efficient and cost-effective way to reduce the burden of cancer in individuals at high risk of developing cancer (Tuffaha et al., 2018). However, *BRCA1* and *BRCA2* variants of uncertain clinical significance (VUS) identified by diagnostic testing continue to pose a challenge for management of patients and their relatives.

ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) is an international research consortium focused on developing and applying methods to determine the clinical significance in breast-ovarian cancer predisposition genes (Spurdle et al., 2012). ENIGMA has developed variant classification criteria that utilize both quantitative (statistical) and qualitative (rules-based) methods to assess the clinical significance of variants in

BRCA1 and *BRCA2* (<http://enigmaconsortium.org/>). Quantitative classifications of variants by ENIGMA are derived from the multifactorial likelihood model (Goldgar et al., 2004; Goldgar et al., 2008) that combines multiple lines of clinical data in a Bayesian framework, with the assumption that each feature is an independent predictor of variant pathogenicity. The *BRCA1/2* model components include likelihood ratios (LRs) for pathogenicity estimated from clinical data, such as co-segregation with disease, co-occurrence with a pathogenic variant in the same gene, reported family history, breast tumor pathology, and more recently, case-control data (de la Hoya et al., 2016; Easton et al., 2007; Goldgar et al., 2008; Spurdle et al., 2014; Thompson, Easton, & Goldgar, 2003). This information is combined with a prior probability of pathogenicity based on bioinformatic predictions of variant effect on protein sequence or messenger RNA (mRNA) splicing (Tavtigian, Byrnes, Goldgar, & Thomas, 2008; Vallee et al., 2016), probabilities that have been calibrated against clinical information, to produce a quantitative classification applicable across many variant types. It should be noted that the reference sets used to derive estimates of these LRs and prior probabilities were selected such that the model is designed to assess if a variant demonstrates the clinical features observed for a classical "high risk" variant. To date there are 297 entries on the *BRCA1/2* database displaying variants classified by this method (<http://hci-exlovd.hci.utah.edu/home.php>), and for which there has been publication of the breakdown of LRs for each component.

The American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) developed a formal framework for using qualitative criteria for variant classification, in an attempt to standardize the application of such evidence (Richards et al., 2015). These guidelines are intended to be generic, and thus some evidence codes will not be relevant for

variant curation for a specific gene. The ClinGen consortium (Rehm et al., 2015; <https://www.clinicalgenome.org/>) has engaged with expert groups to develop adaptations of the guidelines to specify which rule codes and strengths are appropriate for a specific gene-disease relationship, and to provide guidance on the phenotypic features that are most predictive of variant pathogenicity (Rivera-Munoz et al., 2018). To date, adaptations of the ACMG/AMP criteria have been completed for two hereditary cancer genes: *PTEN* (Mester et al., 2018) and *CDH1* (Lee et al., 2018), whereas other gene-adaptations are in development. In addition, ClinGen has approved two additional expert panels arising from pre-existing international research consortia, for the curation of variants in the mismatch repair genes (InSiGHT, International Society for Gastrointestinal Hereditary Tumours; <https://www.insight-group.org>), and in *BRCA1* and *BRCA2* (ENIGMA; <http://enigmaconsortium.org/>). The classification criteria used by these groups pre-dated the development of ACMG/AMP adaptations, and use quantitative methods (as noted above) and qualitative criteria not yet cross-mapped to ACMG/AMP codes. The ClinGen Sequence Variant Interpretation Working Group recently demonstrated that the ACMG/AMP criteria were broadly compatible with Bayesian statistical reasoning, and estimated LR ranges appropriate for code strengths (Tavtigian et al., 2018).

Reference data is essential to calibrate the appropriate gene-specific strength of different curation evidence types, and also to assess if evidence strength is the same for variants with different molecular effects. In relation to *BRCA1* and *BRCA2*, most variants established to be pathogenic are premature truncation variants (including nonsense or frameshift), and thus comprise the majority of variants in reference sets used to calibrate predictors of *BRCA1/2* variant pathogenicity. We have collated data from >40 clinical sites within ENIGMA and from other international clinical collaborators to conduct the largest application of the multifactorial likelihood model to missense and intronic variants in *BRCA1* and *BRCA2*, providing quantitative variant classifications, and also scores for the component data types so as to demonstrate their relative contributions to the final posterior probability. We have also demonstrated the value of this dataset as a resource for calibrating qualitative information for application to *BRCA1/2* variant classification, and deriving *BRCA1/2*-appropriate rule strengths for several ACMG/AMP evidence codes.

2 | METHODS

2.1 | Variant selection for data collection

At the time of joining ENIGMA, members were asked to submit all variants in *BRCA1* and *BRCA2* that they considered to be of uncertain clinical significance, together with the number of families carrying each variant. We followed the rationale that high-risk variants will not occur commonly in the general population, as indicated by frequency measured in outbred reference datasets representative of subpopulations. Variants were thus classified as Class 1 Not Pathogenic if they were identified to occur at minor allele frequency >0.01 in one or more of the following datasets:

South Asian, Latino, African, East Asian, Non-Finnish European subpopulations from the Exome Aggregation Consortium (ExAC) dataset (after excluding cancer-related information from The Cancer Genome Atlas (TCGA; <http://exac.broadinstitute.org>); European, African, Admixed American, East Asian, or South Asian sample sets from the 1000 Genomes Project (<http://www.1000genomes.org>). This exercise provided a baseline variant list for subsequent ENIGMA studies. For the analysis presented in this study, a subset of variants were prioritized for collection of segregation and breast tumor pathology data, based on number of observations/families in the initial ENIGMA variant list and/or bioinformatic score indicative of pathogenicity. Information for cosegregation analysis was provided in the form of a deidentified pedigree for families with known carrier status in more than one individual. Pedigree details included sex, cancer status, and age at cancer diagnosis, or age at interview if unaffected. Unaffected individuals known to have undergone prophylactic surgery (mastectomy or oophorectomy) were censored at age of earliest surgery. Breast tumor pathology information collected for known variant carriers included hormone receptor status (estrogen receptor [ER], progesterone receptor [PR], human epidermal growth factor receptor 2 [HER2]), and/or tumor grade. In addition, clinical queries to the Spurdle laboratory led to the collation of additional segregation and pathology information of potential value for multifactorial likelihood analysis of individual variants. Further, genotype data generated as part of the iCOGS project was available via collaboration with the Breast Cancer Association Consortium (BCAC) for a subset of variants, from up to 41,141 breast cancer cases and 38,694 controls of European ancestry, and 6,185 breast cancer cases and 6,614 controls of Asian ancestry (Michailidou et al., 2013). Variants included in the iCOGS project were prioritized for genotyping using the same approach as for the baseline ENIGMA variant list, with additional variants selected due to laboratory/bioinformatic evidence for effect on mRNA splicing. For each variant, a positive control DNA from a variant carrier was submitted for genotyping to facilitate calling of these rare variants. Lastly, we included a subset of variants for which multifactorial likelihood analysis results had previously been published, but the final classification reported was not “Class 5 Pathogenic” or “Class 1 Not Pathogenic”, and/or LRs were not all visible in the original publication (Easton et al., 2007; Farrugia et al., 2008; Lindor et al., 2012). Information from all these sources was collated for a total of 3,295 variants. This amalgamated list of variants was then circulated by email to ENIGMA consortium members to invite them to provide additional segregation or pathology information for inclusion in the analysis. Where relevant, additional nonoverlapping pathology or segregation information was sourced directly from publications for inclusion in the analysis. Overall, there were 1,008 informative pathology data points and 895 informative families for segregation analysis from ENIGMA collaborators, clinical enquiries, and nonoverlapping publications (see below for further explanation about LR assignment). After combining all information, at least one data point was available for 1,395 variants.

Variant descriptions are in accordance to HGVS recommendations. Nucleotide numbering corresponds to reference transcripts NM_007294.3 (*BRCA1*) and NM_000059.3 (*BRCA2*). Legacy description is also provided to assist comparison with historical records in the literature; the nucleotide numbering is from nucleotide one of the full gene sequence (Genbank: U14680.1/*BRCA1*; U43746/*BRCA2*) not the ATG initiator codon, and *BRCA1* exon boundaries are from GenBank U14680.1 with exon four missing due to a correction made after the initial description of the gene.

2.2 | Multifactorial likelihood analysis

A Bayesian model was used to combine evidence as previously described (Goldgar et al., 2008). In brief, the prior probability of pathogenicity was assigned based on a combination of Align-GVGD score and MaxEntScan splicing predictions, overlaid with expert knowledge incorporating prediction of variant effect on critical functional protein domains (Tavtigian et al., 2008; Vallee et al., 2016). Applicable prior probability of pathogenicity predictions for single nucleotide variants in *BRCA1* and *BRCA2* are available from the HCI Database of Prior Probabilities of Pathogenicity for Single Nucleotide Substitutions (<http://priors.hci.utah.edu/PRIORS/>). Align-GVGD does not score in-frame insertions and deletions, therefore to estimate prior probabilities for in-frame deletion variants studied, we took the highest Align-GVGD prior of the deleted bases. There were no in-frame exonic insertions included in this study. The higher of the two priors (missense vs. splicing) was assigned for analysis. Co-segregation analysis was performed as described by Thompson et al. (2003) for each family with more than one individual genotyped for the variant. Hazard ratio estimates were taken from Antoniou et al. (2003) for <30, 30–39, 40–49, 50–59, 60–69, 70–79, and 80+ age brackets. For individuals affected with ovarian cancer at 20–29 years, penetrance for ovarian cancer at age 30–39 was applied due to a lack of information in the younger penetrance class (Antoniou et al., 2003). If no age at last update was provided by the submitting center for unaffected individuals, test date was used to infer current age. Breast tumor pathology LRs were assigned based on the estimates in Spurdle et al. (2014), and considered age at diagnosis. When multiple tumors were present in one individual, the first diagnosed tumor with information available was taken, and only a single LR was assigned according to the extent of information available (out of the variables tumor grade, ER, PR, and HER2), following previous recommendations (Spurdle et al., 2014). Likelihood ratios for co-occurrence with a pathogenic variant (*in trans*), and reported family history analysis, were drawn from a previous publication (Easton et al., 2007). Case-control data from the iCOGS project were used to estimate LRs following methods described previously (de la Hoya et al., 2016).

Table S1 summarizes the LRs assigned for each component for each variant with at least one data point. Prior probabilities and LRs were combined to calculate posterior probabilities using Bayes rule: (Prior Probability x Combined LR)/(Prior Probability x [Combined LR + {1 – Prior Probability}]). Where multiple data points were available for a single data type, for example, segregation, LRs were

combined multiplicatively. Using variant *BRCA1* c.131G>T as an example: Prior Probability is 0.81; Combined LR is 6,440.7 (based on LR Segregation (156.17) x LR Pathology (41.24) x LR Co-occurrence (a) x LR Family History (a) x LR Case-Control (a)). Posterior probability is 0.99996, calculated as $(0.81 \times 6440.7) / (0.81 \times [6440.7 + \{1 - 0.81\}])$. Breakdown of clinical data type contributed, and the data sources (submitter, publication source), are shown in Table S2.

It has previously been proposed that a combined LR between 0.5 and 2, in particular if derived from a limited number of data points, provides insufficient observational data to perform a valid integrated analysis (Vallee et al., 2016). This is in accord with the idea that ACMG guidelines intrinsically include an indeterminate zone, between supporting benign and supporting pathogenic, for variants with insufficient or conflicting evidence for pathogenicity. Following this rationale, posterior probabilities of pathogenicity were not calculated for any variant with a combined LR between 0.5 and 2. Posterior probability of pathogenicity was calculated for a total of 734 variants, and classification assigned based on previously published cut-offs proposed for the International Agency for Research into Cancer (IARC) five tier classification scheme (Plon et al., 2008), with some modification of terms used to describe tiers (Spurdle et al., 2019), namely: Class 5 Pathogenic, >0.99; Class 4 Likely Pathogenic, 0.95–0.99; Class 3 Uncertain, 0.05–0.949; Class 2 Likely Benign, 0.001–0.049; and Class 1 Benign, <0.001. The variant classifications, with breakdown of LR components and sources, have been submitted to the following databases for public display:

<http://hci-exlovd.hci.utah.edu/home.php?select_db=BRCA1>

<http://hci-exlovd.hci.utah.edu/home.php?select_db=BRCA2>

2.3 | Datasets providing information for comparison and calibration of qualitative classification criteria

2.3.1 | ClinVar assertions

Variant pathogenicity assertions from ClinVar were taken from the November 2018 XML file. Summary annotation and individual submitter annotations are recorded in Table S1 (columns ClinVar Class Summary, ClinVar Class Details by Submitter). A small number of variants included had previously been reviewed by the ENIGMA *BRCA1/2* Expert Panel, but these have not been specifically annotated as the primary purpose of the comparison with ClinVar assertions was to identify discrepancies with classifications derived from this updated multifactorial likelihood analysis.

2.3.2 | mRNA splicing assay data

Published mRNA splicing assays of *BRCA1* and *BRCA2* variants were collated for a previous ENIGMA project (Walker et al., 2013), a resource which has been updated over time. Details of transcripts observed were recorded, and nomenclature errors for variant and transcripts corrected as necessary. We matched these results against the 1,395 variants included in this study (Table S1). Assays that provided variant allele-specific transcript results from patient-derived

mRNA were noted as being eligible for assessment according to the ENIGMA classification guidelines, and effect on mRNA splicing was coded as none, partial, or complete (column Coded Splicing Effect). All other assay results (including additional assays of patient mRNA that did not measure allele-specific expression, and construct-based assays), were noted as to whether the variants were reported to impact mRNA splicing profile or not (column Allele-Specific Splicing Result Summary). To simplify comparison with broad ACMG code description, the relationship of aberrant transcript/s to protein effect that is premature termination, disruption of clinically important residues was not captured in the mRNA effect codes. Further, to limit these LR measures to variant effect on mRNA splicing only, variants classified as (Likely) Pathogenic that had high bioinformatic prediction of effect on amino acid sequence were presumed to confer pathogenicity via effect on protein function, and excluded from the reference set for derivation of the mRNA splicing LRs. See Table S3 for details of the variants included in mRNA splicing subanalysis, and code assignments.

2.3.3 | Protein functional assay data

Seven relatively recent publications, providing results from different mammalian-based assays of protein function, were chosen for comparison with classifications arising from multifactorial analysis. Five publications were from ENIGMA members and incorporate known pathogenic and known benign missense *BRCA1* or *BRCA2* variants as controls, permitting estimation of sensitivity, and specificity of missense variant pathogenicity: (a) region-limited construct-based transcriptional activation assays of missense variants located across the *BRCA1* Coiled Coil, BRCT1, Linker, and BRCT2 domains (Fernandes et al., 2019); (b) full-length complementary DNA (cDNA) construct-based homologous recombination DNA repair assays of missense variants in the *BRCA2* C-terminal DNA binding domain (Hart et al., 2019); (c) a mouse embryonic stem cell-based assay of *BRCA1* variants assessing the ability of full-length human *BRCA1* cDNA to complement reduced cell proliferation following deletion of a conditional mouse *Brca1* allele, and cisplatin sensitivity (Bouwman et al., 2013); (d) a mouse embryonic stem cell-based assay of *BRCA2* variants assessing the ability of full-length genomic human *BRCA2* to complement loss of cell viability following deletion of a conditional mouse *Brca2* allele, and follow-on homologous recombination assays of *BRCA2*-expressing cells that are able to complement cell lethality (Mesman et al., 2019); and (e) analysis of homologous recombination for *BRCA1* BRCT missense variants expressed in mammalian cells as *BRCT1*-*BRCT2* clones into pcDNA3 (modified)-full-length *Brca1*, followed by measures of human *BRCA1* *BRCT1*-*BRCA2* domain solubility (assayed in bacterial cells), and phosphopeptide-binding properties of the purified BRCT domain variants in vitro (Petitalot et al., 2019). These selected studies were the most recent publications arising from these research groups, and incorporated research results from any prior publications from that group. Two additional publications were selected as they provide results from high-throughput multiplex assays. The first was a

multiplex reporter assay characterizing the effects of 1,056 amino acid substitutions in the first 192 residues of *BRCA1* on homology-directed repair of double strand breaks (Starita et al., 2018). The second was a high-throughput saturation genome editing haploid cell survival assay, measuring functional effect for single nucleotide variants in 13 *BRCA1* exons covering key functional domains (Findlay et al., 2018); targeted genomic DNA sequencing and RNA sequencing were used to quantify variant abundance and infer effect on *BRCA1* function overall (DNA sequencing), and via effect on mRNA production (RNA sequencing); function scores for different exons were normalized by matching median scores for synonymous and nonsense variants to global medians for these variant types. The assay design for five of the seven studies permitted assay of effect on protein only, and not mRNA levels or splicing. We thus excluded “missense” variants that were known to alter mRNA levels or splicing, or were located in the splicing motifs at the start/end of exons, such that comparisons with results from functional studies should all be limited to measures of variant effect on protein only. Effect on function as assigned by the original publication was recoded into one of three tiers (complete, partial, or no functional impact). A total of 77 unique variants assayed by at least one study were available for comparison with multifactorial likelihood classifications. See Table S4 for details of the variants and functional code assignments. For Mesman et al. (2019), results from complementation and homologous recombination assay combined were used to assign final functional effect as per recommendations from those authors. For Petitalot et al. (2019), functional classification was based on a combination of homologous recombination, BRCT solubility, and phosphopeptide binding (from their own study and also reports in the literature), as detailed in Table 1b of the publication (Petitalot et al., 2019).

2.3.4 | Reference population frequency data

Population frequency data were downloaded from the Genome Aggregation Database (gnomAD non-cancer v2.1 dataset; gnomad.broadinstitute.org). Three large in-frame deletion variants classified as Pathogenic were excluded from the population frequency LR estimation analysis, as frequencies are not provided by gnomAD for variants of this type. No large deletion variants were classified as (Likely) Benign. As an exercise to compare the validity of gnomAD as a “control” reference dataset, we also compared the frequency of 17 variants detected at allele frequency <1% in European ancestry breast cancer-free controls ($n = 38,694$) genotyped as part of iCOGS, to frequencies for the same variants observed in (a) non-Finnish Europeans from gnomAD (maximum $n = 59,073$, from genome and exome data combined), and (b) European aged (>70 year old) cancer-free control from the FLOSSIES dataset ($n = 7,325$; <https://whi.color.com/>). Our comparisons of variant frequency in gnomAD to those of “true” controls of European ancestry (Table S5) indicated that variants were more likely to be absent from the smaller FLOSSIES dataset (only 6/17 variants were observed), whereas the frequency category based on the gnomAD non-Finnish Europeans was the same as that for iCOGS European ancestry controls for all 17 variants. The FLOSSIES

African dataset provides allele frequencies based on 2,559 individuals (5,118 alleles), which is considerably smaller than the gnomAD African dataset. For this reason we opted to use only gnomAD outbred (non-founder) sample sets (non-Finnish European [15,316–118,174], African [8,664–23,620], Latino [22,398–35,108], South Asian [21,600–30,526], East Asian [14,012–19,252]) to determine the highest minor allele frequency observed based on exome and genome data combined. Variants observed only once across all five outbred sample sets were annotated as such for frequency LR estimation (Table S1). Variants absent from all five outbred sample sets, but present once in Finnish or Ashkenazi Jewish sample sets were excluded from the frequency LR estimation (noted as “NA” in column “Frequency Category Assigned for LR derivation” in Table S1).

Designation of LRs to ACMG/AMP rule code strengths were based on LR ranges recently proposed as consistent with ACMG/AMP qualitative rule strengths for future classification in a Bayesian framework (Tavtigian et al., 2018). Namely: supporting evidence for pathogenicity, LR 2.08–4.3; moderate evidence for pathogenicity, LR 4.3–18.7; and strong evidence for pathogenicity; LR 18.7–350. LRs ranges for Benign code strengths were calculated as the inverse of the ranges proposed for Pathogenic code strengths.

3 | RESULTS AND DISCUSSION

An IARC class informative for clinical management (Class 1 Benign, Class 2 Likely Benign, Class 4 Likely Pathogenic, or Class 5 Pathogenic) was reached for 541/734 (74%) of the 734 variants considered to have sufficient information to inform calculation of a posterior probability of pathogenicity (Table S1). The remaining 193/734 variants fell within the wide range of 0.05–0.95 considered inconclusive of variant pathogenicity (Class 3 Uncertain). Overall, only 54 of the 541 variants with posterior probability assigned have previously been assessed using the multifactorial likelihood approach, and in some instances the clinical evidence included previously did not pass thresholds that have since been set for combined LR (between 0.5 and 2) considered informative for quantitative analysis (see Methods). Of the 541 variants falling outside of Class 3 Uncertain, 67 (9% of the 734 assessed) had a posterior probability of pathogenicity > 0.99 (Class 5 Pathogenic), and 27 (4%) had a posterior probability of pathogenicity > 0.95 (Class 4 Likely Pathogenic), classifications which directly influence management of variant carriers and their relatives (Table 1), with 447 (61%) classified as (Likely) Benign. These findings are consistent with the knowledge that the majority of missense and intronic variants in these genes will, a priori, not be associated with a high risk of cancer as they fall outside of or are unlikely to impact BRCA1 or BRCA2 protein functional domains.

Further, we draw attention in particular to two variants (*BRCA2* c.516+1G>T and *BRCA2* c.7007+1G>C) demonstrating differences between multifactorial likelihood-based analysis and the current iteration of ENIGMA “rules-based” qualitative assessment based on mRNA splicing assay data from patient material (Houdayer et al., 2012; Whiley et al., 2011). The splicing assay data, albeit not allele-specific, indicate that both variants impact splicing profile. According

to ENIGMA qualitative classification criteria, the *BRCA2* c.516+1G>T (intron 6) and *BRCA2* c.7007+1G>C (intron 13) variants would be classified as Class 4 Likely Pathogenic based on their location in a donor dinucleotide - in the absence of conflicting information. Despite the high prior probability of 0.97 based on bioinformatic prediction, the clinical information included in this study provided sufficient evidence against pathogenicity that the posterior probability fell below 0.95 (0.81 for *BRCA2* c.516+1G>T, 0.78 for *BRCA2* c.7007+1G>C). For *BRCA2* c.7007+1G>C, the variant was identified in the breast cancer affected proband but not in the one affected relative tested. For *BRCA2* c.516+1G>T, only two of four affected relatives tested were carriers. Although both variants have been submitted to ClinVar as pathogenic by multiple submitters; summary evidence was provided for only one assertion for *BRCA2* c.7007+1G>C, and refers to variant location and splicing assay data with no additional clinical details. Interestingly, unpublished results from mouse embryonic stem cell assays M.P.G. Vreeswijk (personal communication, 22 January 2019) indicate that *BRCA2* c.7007+1G>C has a severe impact on function as measured by failure to complement the lethal cell phenotype, whereas *BRCA2* c.516+1G>T does not have a severe impact on function (complementation; 56% HDR capacity, within the range for variants previously placed in Class 1/2 by multifactorial likelihood analysis). The combined observations for these two variants raise the complex issue of what constitutes sufficient conflicting information when assigning a qualitative classification, or perhaps even in the context of LRs included in a quantitative classification calculation. The current classification in ClinVar as Likely Pathogenic would appear to be consistent with ACMG-derived classifications used in clinical practice, but we strongly recommend prioritized collection of additional clinical, splicing and functional data to provide more extensive information in support of assertions for these two variants.

Overall, comparison of classes assigned by multifactorial likelihood analyses and pathogenicity assertions in ClinVar revealed that of the 94 variants classified as (Likely) Pathogenic by multifactorial likelihood analysis conducted in this study, 80 have at least one assertion as (Likely) Pathogenic, seven are Uncertain, and seven are currently not in ClinVar; that is none were submitted as (Likely) Benign. Of the 447 variants classified as (Likely) Benign using multifactorial analysis, 212 have at least one assertion as (Likely) Benign, 234 were either uncertain in or absent from ClinVar, and the remaining variant *BRCA1* c.5453A>G p.(Asp1818Gly) is actually a spliceogenic variant with four assertions as (Likely) Pathogenic. The explanation for this discrepancy is detailed below. Altogether, these results can now be used to contribute to ENIGMA expert panel classification of 541 variants, 248 of which are new or considerably altered compared to current submissions to ClinVar.

3.1 | Correlation of multifactorial likelihood classifications with splicing assay data

Current ENIGMA *BRCA1/2* classification criteria for spliceogenic variants, consistent with those of the InSiGHT Consortium developed

TABLE 1 Variants classified as Pathogenic or Likely Pathogenic using multifactorial likelihood analysis^a

Gene	HGVS nucleotide	HGVS protein	Prior probability of pathogenicity	Co-segregation LR	Tumor pathology LR	Co-occurrence LR	Family history LR	Combined LR	Posterior probability of pathogenicity	IARC 5-tier class
BRCA1	c.131G>T	p.(Cys44Phe)	0.81	156.17	41.24			6,440.72	1.000	P
BRCA1	c.135-1G>T		0.97	9,528.00	2.01			19,140.38	1.000	P
BRCA1	c.140G>A	p.(Cys47Tyr)	0.81	13,545.00	60.31			816,898.95	1.000	P
BRCA1	c.191G>A	p.(Cys64Tyr)	0.81	5,300,394.00	189.09			1,002,254,925.72	1.000	P
BRCA1	c.211A>G	p.(Arg71Gly)	0.81	383.27				383.27	0.999	P
BRCA1	c.212+1G>A		0.97	1,794.18	3.73			6,692.28	1.000	P
BRCA1	c.212+1G>T		0.97	7.65	3.34			25.56	0.999	P
BRCA1	c.213-12A>G		0.97	29,429.38	1,132.14			33,318,129.21	1.000	P
BRCA1	c.302-2del		0.97	58,263.44	387.67	1.43	1.87	60,436,990.13	1.000	P
BRCA1	c.3G>T	p.(Met1?)	0.96	1.97	3.73			7.36	0.994	P
BRCA1	c.4097-2A>G		0.97	0.42	9.99			4.20	0.993	P
BRCA1	c.4185+2_4185+22delinsA		0.96	0.33	30.65	1.26	28.61	358.47	1.000	P
BRCA1	c.4185G>A	p.(=)	0.97	39.32	13.91			547.01	1.000	P
BRCA1	c.4357+1G>T		0.97	0.67		1.14	6.63	5.10	0.994	P
BRCA1	c.4484+1del		0.97	0.33	28.14			9.22	0.997	P
BRCA1	c.4484G>C	p.(Arg1495Thr)	0.34	27.73	9.99			276.94	0.993	P
BRCA1	c.4485-1G>T		0.97			1.03	11.76	12.15	0.997	P
BRCA1	c.4675+3A>T		0.97			1.03	4.18	4.31	0.993	P
BRCA1	c.4675G>A	p.(Glu1559Lys)	0.97	1.79		1.26	3.48	7.84	0.996	P
BRCA1	c.4676-1G>A		0.97	3.75		2.92	32.31	353.30	1.000	P
BRCA1	c.4986+6T>G		0.97	18.94	1,134.07			21,484.60	1.000	P
BRCA1	c.4987-2A>G		0.97	1.99	9.70	1.05		20.20	0.998	P
BRCA1	c.5062_5064del	p.(Val1688del)	0.66	16.93		1.18	13.41	267.23	0.998	P
BRCA1	c.5074+1G>T		0.97	13.92	1.69	1.10	1.18	30.64	0.999	P
BRCA1	c.5074+2T>C		0.97	2.43	3.73	1.07	7.31	70.75	1.000	P
BRCA1	c.5074G>C	p.(Asp1692His)	0.97	1.91	3.73	1.25	0.90	8.02	0.996	P
BRCA1	c.5089T>C	p.(Cys1697Arg)	0.81	730.63	2.41			1,758.02	1.000	P
BRCA1	c.5144G>A	p.(Ser1715Asn)	0.66	57.86	3.73	1.30	3.63	1,016.90	0.999	P
BRCA1	c.5153-1G>A		0.97			1.22	3.11	3.78	0.992	P
BRCA1	c.5277+1_5277+6del		0.97			1.03	15.10	15.60	0.998	P
BRCA1	c.53T>C	p.(Met18Thr)	0.66	1.84	5.28	1.22	25.48	300.74	0.998	P

(Continues)

TABLE 1 (Continued)

Gene	HGVS nucleotide	HGVS protein	Prior probability of pathogenicity	Co-segregation LR	Tumor pathology LR	Co-occurrence LR	Family history LR	Combined LR	Posterior probability of pathogenicity	IARC 5-tier class
BRCA1	c.5468-1G>A		0.97	2.10	41.24	1.03	1.24	110.47	1.000	P
BRCA1	c.547+1G>T		0.97	1.95	1.67			3.25	0.991	P
BRCA1	c.5509T>C	p.(Trp1837Arg)	0.81	183.54	0.73	1.14	0.19	28.33	0.992	P
BRCA1	c.5516T>C	p.(Leu1839Ser)	0.66	21.96	51.90			1,139.69	1.000	P
BRCA1	c.81-9C>G		0.97			1.07	8.13	8.67	0.996	P
BRCA2	c.(?-227)_67+?del	p.?	0.96	13.34	1.17			15.56	0.997	P
BRCA2	c.3G>A	p.(Met1?)	0.96	67.62	2.17	1.07		157.49	1.000	P
BRCA2	c.475+1G>T		0.97	1.90		1.21	9.19	21.21	0.999	P
BRCA2	c.517-2A>G		0.97	3.50	3.82	1.28	3.12	53.08	0.999	P
BRCA2	c.631+2T>G		0.97	22.51	0.81			18.28	0.998	P
BRCA2	c.632-1G>A		0.97	95.33	2.21			210.58	1.000	P
BRCA2	c.632-2A>G		0.97	152.33	0.79	1.05	0.18	23.32	0.999	P
BRCA2	c.632-3C>G		0.97			1.05	3.60	3.78	0.992	P
BRCA2	c.67+1G>T		0.97	3.91	1.19	1.05	1.48	7.21	0.996	P
BRCA2	c.6938-2A>G		0.97			1.08	5.30	5.70	0.995	P
BRCA2	c.7007G>A	p.(Arg2336His)	0.34	48.57	0.83	2.46	20.33	2013.98	0.999	P
BRCA2	c.7008-?_7805+?del		0.81	2,786.04	18.12			50,481.75	1.000	P
BRCA2	c.7008-1G>A	p.(=)	0.97	2.00	1.79			3.57	0.991	P
BRCA2	c.7008-2A>G		0.97	1.52		1.02	2.50	3.90	0.992	P
BRCA2	c.7617+2T>G		0.97	2.72	0.81	1.08	1.59	3.75	0.992	P
BRCA2	c.7618-2A>G		0.97	1.30	1.96	1.03	2.29	6.03	0.995	P
BRCA2	c.7806-2_7806-1dup		0.99	8.77	4.38			38.36	1.000	P
BRCA2	c.7806-2A>G		0.97	7.11	1.20	1.41	1.67	20.04	0.998	P
BRCA2	c.7975A>G	p.(Arg2659Gly)	0.81	1,950.00	0.86	1.10	5.07	9,380.28	1.000	P
BRCA2	c.7976+1G>A		0.97	0.71		1.22	160.57	138.22	1.000	P
BRCA2	c.7977-1G>C		0.97	1,984,739.68	10.20			20,246,907.80	1.000	P
BRCA2	c.8023A>G	p.(Ile2675Val)	0.64	605.14	0.88	1.05	2.88	1,612.05	1.000	P
BRCA2	c.8488-1G>A		0.97			1.13	3.73	4.21	0.993	P
BRCA2	c.8632+1G>A		0.97	21.93	0.74			16.19	0.998	P
BRCA2	c.8633-24_8634del		0.97			1.05	3.16	3.32	0.991	P

(Continues)

TABLE 1 (Continued)

Gene	HGVS nucleotide	HGVS protein	Prior probability of pathogenicity	Co-segregation LR	Tumor pathology LR	Co-occurrence LR	Family history LR	Combined LR	Posterior probability of pathogenicity	IARC 5-tier class
BRCA2	c.8633-2A>G		0.97	1.29	1.06	1.05	6.65	9.58	0.997	P
BRCA2	c.8755-1G>A		0.97	9.40	2.85	1.31	8.13	284.48	1.000	P
BRCA2	c.8954-1_8955delinsAA		0.97			1.28	3.77	4.81	0.994	P
BRCA2	c.9118-2A>G		0.97	10.89	0.51			5.56	0.994	P
BRCA2	c.9257-?(*_1_?)del		0.81	31.48	3.10			97.53	0.998	P
BRCA2	c.9371A>T	p.(Asn3124Ile)	0.81	402.919.02	0.54	2.07	81.64	36,698,863.68	1.000	P
BRCA1	c.181T>A	p.(Cys61Ser)	0.81	1.39	3.73			5.19	0.957	LP
BRCA1	c.1A>G	p.(Met1?)	0.96	1.27	2.23			2.83	0.985	LP
BRCA1	c.230_238del	p.(Thr77_Phe79del)	0.66	1.83	16.45			30.16	0.983	LP
BRCA1	c.4185_4185+3del		0.97	2.09		1.048		2.19032	0.986	LP
BRCA1	c.4185+1G>T		0.97		3.16	1.10	2.64	2.91	0.989	LP
BRCA1	c.4479_4484+2dup		0.97	0.96				3.04	0.990	LP
BRCA1	c.4676-2A>G		0.97			1.03	2.29	2.36	0.987	LP
BRCA1	c.5193+1G>A		0.97	1.27	1.67			2.12	0.986	LP
BRCA1	c.5207T>G	p.(Val1736Gly)	0.81			1.10	6.53	7.20	0.968	LP
BRCA1	c.5213G>A	p.(Gly1738Glu)	0.81	1.18		1.18	8.89	12.30	0.981	LP
BRCA1	c.5216A>T	p.(Asp1739Val)	0.81	0.82		1.03	7.93	6.72	0.966	LP
BRCA1	c.5243G>A	p.(Gly1748Asp)	0.81	3.80	3.16	1.03	0.92	11.47	0.980	LP
BRCA1	c.5333-6T>G		0.97	0.68	3.73			2.55	0.988	LP
BRCA1	c.5558A>G	p.(Tyr1853Cys)	0.81	12.66	0.40	1.07	2.29	12.39	0.981	LP
BRCA1	c.80+5G>A		0.34	15.05	1.49	1.03	2.60	60.32	0.969	LP
BRCA2	c.476-1G>A		0.97	1.23		1.02	2.18	2.75	0.989	LP
BRCA2	c.67+2T>C		0.97		1.08	1.13	1.86	2.10	0.985	LP
BRCA2	c.681+1G>A		0.97	1.94				2.10	0.985	LP
BRCA2	c.7007+5G>C		0.34	8.55	0.95	1.08	4.75	41.64	0.955	LP
BRCA2	c.7819A>C	p.(Thr2607Pro)	0.66			1.02	11.62	11.90	0.959	LP
BRCA2	c.8009C>T	p.(Ser2670Leu)	0.29	17.87	4.74	1.37	1.22	141.76	0.983	LP
BRCA2	c.8035G>T	p.(Asp2679Tyr)	0.81	3.54	1.06	1.02	1.24	4.76	0.953	LP
BRCA2	c.8331+1G>A		0.97			1.02	2.72	2.79	0.989	LP
BRCA2	c.8331+1G>T		0.97	1.17	1.77			2.07	0.985	LP

(Continues)

TABLE 1 (Continued)

Gene	HGVS nucleotide	HGVS protein	Prior probability of pathogenicity	Co-segregation LR	Tumor pathology LR	Co-occurrence LR	Family history LR	Combined LR	Posterior probability of pathogenicity	IARC 5-tier class
BRCA2	c.8754+4A>G		0.34	4.87	3.13	1.34	2.22	45.36	0.959	LP
BRCA2	c.8975_9100del	p.(Pro2992_Thr3033del)	0.81			1.24	13.48	16.78	0.986	LP
BRCA2	c.9257-1G>C		0.34	1.29	0.76	1.16	47.50	54.24	0.965	LP

Abbreviations: HGVS, Human Genome Variation Society; LP, Likely Pathogenic; LR, likelihood ratio; P, Pathogenic.

^aSee methods for overview of sources of information, and multifactorial likelihood analysis methods. Case-control LR data were not available for any variants classified as (Likely) Pathogenic.

for classification of mismatch repair gene variants (Thompson et al., 2014), present stringent recommendations for use of mRNA splicing data for variant interpretation (<https://enigmaconsortium.org>). Namely, a variant is only considered pathogenic on the basis on mRNA splicing data if there is no predicted functional transcript produced from the variant allele, as determined by assays of patient-derived mRNA that have assessed allele-specific expression of alternate transcripts. This stipulation is not specified for ACMG/AMP classification codes using splicing data (PS3, well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product).

We undertook a comparison of multifactorial model classifications against published splicing assays results (including assays of patient material and construct-based assays) to calibrate use of splicing assay data for use as weighted information for qualitative classification, based on the LR ranges recently proposed as consistent with ACMG/AMP qualitative rule strengths for future classification in a Bayesian framework (Tavtigian et al., 2018). Of the variants falling outside of Class 3 Uncertain in this analysis, 99 had mRNA splicing data available, 25 of which had been assessed using allele-specific assays of mRNA from patient tissue. By comparing splicing effect to classifications derived from this study, we estimated a LR towards pathogenicity based on effect on mRNA splicing (Table 2; Table S3 for additional details). The very limited number of allele-specific assays did not allow for robust estimates of LRs, with the confidence intervals for LRs estimated for both partial and complete effect on splicing including unity. Nevertheless, results support the hypothesis that partial effect on splicing will not be as strongly predictive of pathogenicity as is complete effect on splicing (LR 3.82 vs. LR 6.36 from this analysis). Including all assay results, no effect on splicing provided strong evidence against pathogenicity (LR 0.02), whereas any impact on splicing (without measurement of allele-specific effects, or consideration of in-frame transcripts) provided moderate evidence for pathogenicity (LR 12.24). Recognizing the small sample sizes, and consequently large confidence limits, these results nevertheless demonstrate the value of mRNA splicing assays as a component in qualitative variant classification. We also highlight the possibility that there is likely to be considerable bias in variants selected for mRNA assays, with over-representation of variants at the highly conserved donor and acceptor dinucleotides, positions that, when altered, are likely to impact splicing more severely than spliceogenic variants located at other positions. We thus stress the importance of incorporating allele-specific expression assays into variant evaluation processes wherever possible, and to revisit such analysis with larger datasets in the future. We also recommend that future larger-scale comparisons to derive LRs for splicing assay data should consider in greater detail the predicted impact of the aberrant mRNA profiles on protein function, and in particular consider the relevance of in-frame isoforms that could be translated to result in (partially) functional protein. Further, as both partial mRNA splicing and in-frame transcripts may be associated with reduced cancer penetrance that is not inherently captured by the design of the multifactorial model, family-based and case-control studies may be

TABLE 2 Splicing effect reported for variants classified as (Likely) Benign or (Likely) Pathogenic using multifactorial likelihood analysis^a

Splicing effect	(Likely) benign		(Likely) pathogenic		LR towards pathogenicity	(95% confidence interval)
	n	%	n	%		
<i>Assays measuring allele-specific expression</i>						
None	11	78.57	0	9.09 ^b	0.12	(0.02–0.76)
Partial	2	14.29	6	54.55	3.82	(0.95–15.36)
Complete	1	7.14	5	45.45	6.36	(0.86–46.86)
<i>Total</i>	14		11			
<i>All splicing results</i>						
None	46	92.00	0	2.04 ^b	0.02	(0.01–0.15)
Any impact	4	8.00	49	97.96	12.24	(4.78–31.35)
<i>Total</i>	50		49			

^aSee methods for overview of sources of mRNA splicing information, and categorization of splicing effect. Also see Table S3 for details of variants included in comparison.

^bPercentage is calculated assuming a single variant in this category, and thus provides a conservative estimate of the LR.

necessary to tease out which such spliceogenic variants are indeed risk-associated, and if this level of risk is clinically actionable.

We then considered qualitative classification based on mRNA splicing results for all variants with a multifactorial likelihood calculation that is including Class 3 Uncertain variants (See Table S1, columns Splicing Results/s and Allele-Specific Assay). Following ENIGMA *BRCA1/2* qualitative classification criteria (<http://enigmaconsortium.org/>), there were 15 variants that could be interpreted as Pathogenic based on splicing, that is no predicted functional transcript produced from the variant allele; of these, multifactorial data classified five as (Likely) Pathogenic, five as Uncertain, whereas four had insufficient data to perform a calculation. *BRCA1* c.5453A>G was the only variant with truly discordant classification between splicing results (Class 5 Pathogenic) and multifactorial data analysis (Class 2 Likely Benign); the multifactorial classification was based on low prior probability of 0.03 for the presumed missense substitution Asp1818Gly, one pathology data point (LR 0.34), and relatively uninformative co-occurrence (LR 1.12) and family history (LR 0.91) data. This variant highlights a recognized limitation of current bioinformatic predictions used in the multifactorial analysis; the variant alters splicing by modifying an exonic splice enhancer (ESE; Rouleau et al., 2010). There are currently no bioinformatic prediction tools with adequate sensitivity and specificity to predict ESE loss or gain with any reliability, and this mechanism has thus not yet been incorporated into bioinformatic prior probability estimation. Although results from splicing assays can obviously add value for such examples, the poor predictability of ESEs and effects of variation on ESE function, hinders the prioritization of ESE-altering variants for splicing assays. We reiterate that the Class 2 Likely Benign tier implicitly allows for a 5% error rate in classification, and resources permitting, we would encourage additional data collection for all variants falling in this tier. Moreover, future inclusion of a LR derived for splicing impact as a component of the multifactorial likelihood analysis, where such splicing information is available, would likely shift the posterior probability for such variants into the range of Class 3 Uncertain and so prevent overt misclassification driven by

bioinformatic prediction deficiencies. At this point in time, we would encourage additional clinical data collection for *BRCA1* c.5453A>G to confirm that the clinical phenotype is consistent with a Class 5 Pathogenic assertion based on splicing data only.

3.2 | Correlation of multifactorial likelihood classifications with protein functional assay data

Functional assays are considered strong evidence for or against pathogenicity using ACMG/AMP codes PS3 and BS3 (well-established in vitro or in vivo functional studies show (damaging/no damaging) effect on gene or gene product). A range of different assays have been used to assess effect of *BRCA1* and *BRCA2* variants on protein function, some limited to measuring impact on function of variants within a specific domain, and others measuring output relevant to a variant located anywhere in the coding region. To assess the strength of this evidence as a predictor of the clinical significance of anticipated missense *BRCA1* and *BRCA2* variations, it is important to consider several factors. Sensitivity and specificity of assays should be determined using missense variants that have previously been determined to be pathogenic or benign (Guidugli et al., 2014; Millot et al., 2012); that is assay profiles for truncating variants may not be appropriate to measure loss of function displayed by pathogenic missense variants. To prevent circularity, functional assay results should not have contributed to the classification of these “control” missense variants, as may be the situation for variants submitted to ClinVar as pathogenic. An additional factor to consider, but not addressable at this point in time, is that there are few *BRCA1/2* variants robustly proven to be associated with moderate risk of cancer. There is thus a paucity of controls to calibrate assay results to detect moderate-risk variants. Moderate-risk variants are intuitively expected to have less impact on function than variants associated with a high cancer risk comparable to that of the average truncating allele, and severity of their impact on function may differ depending on the specific protein effects measured (Lovelock et al., 2007).

For this reason, we compared our multifactorial analysis results for missense variants classified outside of Class 3 Uncertain to results from selected published functional assays (also see Methods). Briefly, these included: (a) domain-specific or generic assays assessing variant effect on protein function, and calibrated against missense variants previously classified as pathogenic or benign using multifactorial likelihood analysis that is using bioinformatic and clinical information (Bouwman et al., 2013; Fernandes et al., 2019; Hart et al., 2019; Mesman et al., 2019; Petitalot et al., 2019); and (b) multiplex reporter assays (Findlay et al., 2018; Starita et al., 2018) reported to have reasonable to good sensitivity and specificity by comparison to ClinVar classifications (including truncating, splicing, and missense variants). There were 16 (Likely) Pathogenic and 61 (Likely) Benign variants with a protein functional assay result from at least one study (Table 3; Table S4 for additional details). All 56 variants reported to have no functional impact were classified as (Likely) Benign, as were the four of five variants demonstrating partial function in at least one assay. The fifth variant *BRCA1* c.5216A>T p.(Asp1739Val) was classified as Likely Pathogenic based on posterior probability of 0.97. As outlined in Supp Table S4, this missense substitution variant was reported to have complete loss of function using transcription activation and cell survival assays, but partial activity by Petitalot et al. (2019); the latter categorization was based on the combination of somewhat decreased solubility, decreased BACH1 binding (reported in yet another publication, Lee et al. (2010)), and normal homologous recombination and localization (Petitalot et al., 2019). Of the 16 variants reported to impact function completely (and with no evidence otherwise by another of the functional studies selected), 15 were classified by multifactorial likelihood analysis as (Likely) Pathogenic, and the other as (Likely) Benign. Of note, the latter variant *BRCA2* c.8351G>A p.(Arg2784Gln) did complement lethality in the mouse embryonic stem cell assay (Mesman et al., 2019), but was coded as impacting function based on homologous recombination assay results from the same study (Mesman et al., 2019), and was reported to impact homologous recombination in an independent study (Hart et al., 2019). We note that for the two exceptions highlighted

(*BRCA1* c.5216A>T, *BRCA2* c.8351G>A), the results from survival assays were concordant with the multifactorial likelihood classification.

Considering results overall, we estimated a LR towards pathogenicity based on assays of protein function from at least one study (Table 3). Acknowledging the caveat of small sample sizes, and at least one observation (and thus liberal frequency estimates) assumed for cells without counts, our results support use of functional assay data as moderate or strong evidence in determining pathogenicity assertions for missense variants. Specifically, complete impact on function with no conflicting evidence is strongly predictive of missense variant pathogenicity (estimated LR 57.19, lower confidence bound 8.15). No impact on protein function provides moderate evidence against missense variant pathogenicity (LR 0.07 with upper bound 0.45, equating to an LR of 15.26 against pathogenicity). The results confirm the value of results from these selected protein functional assays as a component in qualitative classification of missense variants. They also stress the importance of considering discordances across different assay methods as an approach to select individual variants for further consideration as potential moderate-risk variants, variants that may not always be detectable as risk-associated using statistical models developed for high-risk variants. Further, as noted before, the *BRCA1/2* multifactorial model is designed to capture clinical features of patients with the average high-risk pathogenic variant, and we cannot exclude the possibility that some variants demonstrating impact on function (partial, or even complete for at least one assay type) are moderate-risk alleles. It will thus be important to prioritize variants such as *BRCA1* c.5216A>T p.(Asp1739Val) and *BRCA2* c.8351G>A p.(Arg2784Gln), where some functional data conflict the clinical information data (thereby arguably considered Uncertain according to ACMG/AMP qualitative criteria) for further study as potential moderate-risk variants.

3.3 | Correlation of multifactorial likelihood classifications with frequency in reference population datasets

Variant frequency in disease-free controls can be used to provide evidence against pathogenicity, and indeed minor allele frequency

TABLE 3 Functional effect reported for missense substitution variants classified as (Likely) Benign or (Likely) Pathogenic using multifactorial likelihood analysis^a

Protein functional effect in at least 1 study ^b	(Likely) benign		(Likely) pathogenic		LR towards pathogenicity	(95% confidence interval)
	n	%	n	%		
None	56	91.80	0	6.25 ^c	0.07	(0.01–0.45)
None/partial	3	4.92	0		N/A	
Partial	1	1.64	0		N/A	
Partial/complete	0		1	6.25	N/A	
Complete	1	1.64	15	93.75	57.19	(8.15–401.14)
<i>Total</i>	<i>61</i>		<i>16</i>			

^aExcludes missense variants shown to be associated with altered mRNA splicing, or with reduced/absent mRNA expression from survival assays. See Table S4 for details of variants included in comparison.

^bFunctional impact codes assigned based on effect description as originally published. See Table S4 for more details.

^cPercentage is calculated assuming a single variant in this category, and thus provides a conservative estimate of the LR.

TABLE 4 Frequency in reference population control sets for variants classified as (Likely) Benign or (Likely) Pathogenic using multifactorial likelihood analysis^a

Frequency category	(Likely) benign		(Likely) pathogenic		LR towards pathogenicity	(95% confidence interval)
	n	%	n	%		
Single observation	59	13.32	8	8.99	0.67	(0.33–1.36)
≥ 0.0001 & < 0.01	110	24.83	0	1.12 ^b	0.05	(0.01–0.32)
> 0 & < 0.0001	119	26.86	3	3.37	0.13	(0.04–0.39)
Not observed	155	34.99	78	87.64	2.50	(2.16–2.91)
Total	443		89			

^aSee methods for details of control datasets and assignment of frequency category.

^bPercentage is calculated assuming a single variant in this category, and thus provides a conservative estimate of the LR.

(MAF) > 1% in a nonfounder population is considered stand-alone evidence against pathogenicity for *BRCA1/2* variants by the ENIGMA consortium. An algorithm to define a “maximum credible population allele frequency” (Whiffin et al., 2017) has been proposed as a method to select MAF cut-offs as evidence against pathogenicity, and indeed was used as a basis to select relevant minor allele frequency cut-offs for the *PTEN* and *CDH1* adaptations of ACMG/AMP rule codes BA1 (stand-alone) and BS1 (strong) evidence against pathogenicity, described as “allele frequency is greater than expected for the disorder.” The output of this algorithm can vary widely depending on input assumptions for disease penetrance and prevalence of the disorder, and is complicated for multicancer syndromes where penetrance varies for cancer type and even cancer subtype. Further, absence from control datasets has been proposed as moderate evidence for variant pathogenicity (ACMG/AMP rule code PM2).

The most commonly used “control” reference sets (ExAC, and more recently gnomAD) include males and females that were ascertained for noncancer related studies mostly at ages younger than the average age at onset of *BRCA1/2*-related breast or ovarian cancer, but individual-level information about cancer phenotypes is not available. Even assuming that these reference sets are largely cancer unaffected, it must be considered that penetrance in female pathogenic variant carriers for breast cancer is not complete, and much lower for male carriers. Indeed, known pathogenic *BRCA1/2* variants have been identified in these population control sets, even after accounting for “founder” pathogenic variants (Maxwell, Domchek, Nathanson, & Robson, 2016). As a result, the current ENIGMA *BRCA1/2* classification guidelines used empirical data to select frequency cut-offs for qualitative classification criteria (<https://enigmaconsortium.org/>). Specifically, allele frequency ≥ 0.001 and < 0.01 in large outbred control reference groups was selected as a component of evidence against pathogenicity, based on the upper 95% confidence interval (binomial Exact) of the frequency observed for the most common pathogenic allele in non-Finnish European and other population groups drawn from ExAC and gnomAD. The absence from controls has not yet been incorporated into the ENIGMA *BRCA1/2* guidelines.

To determine the utility of variant frequency in (or absence from) reference population sets for future *BRCA1* and *BRCA2* variant classification, and to formally assess the strength of this evidence, we

estimated a LR based on MAF in gnomAD v2.1 (noncancer), and considered them against LR cut-offs suggested for ACMG/AMP rules (Tavtigian et al., 2018). Results are shown in Table 4. We considered variants observed only once across all sample sets reviewed as a separate category (see Methods), and categorized the remaining variants into three MAF bins: $0.01 > \text{MAF} \geq 0.0001$; $0 < \text{MAF} < 0.0001$; and not observed. The proportion of variants seen only once across all five sample sets was 13.32% for (Likely) Benign variants compared with 8.99% for (Likely) Pathogenic Variants, which equates to an LR of 0.67, considered uninformative for pathogenicity prediction. Variants classified as (Likely) Benign were spread relatively evenly across the frequency categories, whereas (Likely) Pathogenic variants were only seen at $\text{MAF} < 0.0001$, and the vast majority (88%) were not seen in population controls. Assuming conservatively a single (Likely) Pathogenic variant to fall in the category “ ≥ 0.0001 & < 0.01 ,” the LR estimate is 0.05, equating to an LR of 22.10 (3.12–156.21) against pathogenicity, considered strong evidence that a variant is benign. The estimated LR against pathogenicity for a variant seen in gnomAD at $\text{MAF} < 0.0001$ is 7.97 (2.59–24.50), which meets moderate evidence against pathogenicity. Last, the estimated LR towards pathogenicity for a variant not detected in gnomAD is 2.50 (2.16–2.91), corresponding to supporting evidence in favor of pathogenicity; these findings suggest that whereas “absence in controls” may be useful for *BRCA1/2* variant classification, such evidence should carry less weight than the PM2 moderate code proposed by ACMG/AMP for generic use.

Overall, these findings, based on empirical data, have utility to inform the ongoing adjustment of the ENIGMA *BRCA1/2* guidelines. Use of these frequency cut-offs for variants designated in this study (Table S1) as Class 3 Uncertain or with posterior probability not calculated, suggests strong evidence against pathogenicity for 98 variants, moderate evidence against pathogenicity for 147 variants, and supporting evidence in favor of pathogenicity for 468 variants. It is relevant to acknowledge that some variants detected in public databases - and also in clinical datasets - may be somatic rather than germline in origin, arising due to clonal hematopoiesis of indeterminate potential. However, the proportion of variants arising due to this mechanism is expected to be rare for *BRCA1* and *BRCA2* (estimated as < 0.2% of all pathogenic variants in one study of > 200,000 cancer gene tests (Coffee et al., 2017)), and we would also

anticipate that the majority of such variants would be filtered out by generic allele fraction cut-offs used by sequencing pipelines set up to detect true germline variants.

3.4 | Caveats, considerations, and conclusions

This study is the largest presentation of multifactorial likelihood analysis to date. Although we mined existing public data and requested clinical data for calculations from more than 300 individuals on the ENIGMA mailing list, we recognize that the classifications assigned may alter with addition of data from other sources, and/or with the application of qualitative classification criteria. Efforts to collate information in a transparent manner that retains patient confidentiality, and within the bounds of ethical constraints, remain a challenge. As one step towards transparency, we present summary estimates of LRs for the individual components included in the analysis, and the sources of the different information types. Further discussion, and probably technical developments, will be required to determine how more detailed information, for example, segregation scores for individual families, may be presented for future large-scale studies.

A prepublication iteration of the classification dataset was used as a reference set for the Critical Assessment of Genome Interpretation (CAGI) 5 experiment, results from which are presented in this same *Journal* issue (Cline et al.,). Comparison of various different prediction methods from six different teams highlighted that prediction of mRNA splicing is an important inclusion in variant interpretation algorithms, and also indicated that variant interpretation may be improved by incorporating amino acid accessibility as a component of bioinformatic prediction of variant effect. It also showed that use of clinical information, when available, provides significant improvements to variant classification over purely bioinformatic approaches. In addition to the CAGI 5 experiment, we chose to use an updated dataset for calibration of isolated data types commonly used as components of qualitative classification approaches. Specifically, the variant classifications from multifactorial likelihood analysis were derived without use of laboratory splicing and functional data, or variant frequency in outbred reference populations. This allowed us to estimate independent LRs for or against pathogenicity for these evidence types, with several purposes: to assess the validity of ACMG/AMP code strengths proposed for these evidence types when applying them to classification of *BRCA1/2* variants; to justify specific ENIGMA *BRCA1/2* classification criteria incorporating population frequency or mRNA splicing data; to provide guidance on incorporation of *BRCA1/2* protein functional assay data, to assess *BRCA1/2* predicted missense variants specifically, in quantitative or qualitative (rules-based) classification models. We acknowledge that further analyses are necessary before such LR estimations be formally reviewed and incorporated into guidelines for *BRCA1/2* Expert Panel variant interpretations. Namely, it will be important to investigate LR estimations with additional variants that have been previously assessed using the multifactorial likelihood approach, and to derive

LRs separately for *BRCA1* and *BRCA2* given differences in the penetrance for truncating variants in these two genes and the potential for differences in sensitivity and specificity of different laboratory assays to detect impact on function. Nevertheless, we note that, despite the fact that known *BRCA1/2* pathogenic variants are seen in reference population datasets, and acknowledging reservations that absence in control populations overall is not a predictor of variant pathogenicity, it appears that this feature does have value for examining the clinical relevance of rarer variants presenting for assessment at this point in time; that is, accounting for the fact that “known pathogenic” variants observed in control datasets are more likely to have already been observed in the clinical setting and already classified using other information types. This observation highlights issues around constancy of evidence strengths over time, and indicates that it will be important to reconsider such analysis periodically to re-estimate LRs and corresponding rule strengths as the pool of variants remaining to be classified alters over time. Following this line of thought, it will be important that estimates of prior probability based on bioinformatic predictions are re-estimated using updated datasets that reflect changed variant pools, and altered patient ascertainment in the era of multigene panel testing. Results arising from the CAGI 5 experiment (Cline et al.,), and other similar studies, are likely to inform development of such bioinformatic methods.

In summary, we have used the multifactorial likelihood analysis approach to generate 248 new or considerably altered *BRCA1/2* variant classifications, information that is relevant for medical management – including determining patient eligibility for screening or PARPi treatment, and cascade testing of their relatives. We have also shown the value of this dataset for confirming existing ClinVar assertions, and for calibration of additional data types useful for variant interpretation. We have provided as supplementary information details regarding data sources and likelihood scores for all variants investigated, so providing a resource that will facilitate continued assessment of variants as additional information accrues, and further calibration of new lines of evidence relevant for variant interpretation.

ACKNOWLEDGMENTS

We acknowledge ENIGMA members for discussions and feedback relevant to variant classification activities, in particular members of the ENIGMA *BRCA1/2* variant classification committee and the Dutch and Belgian hereditary breast cancer gene variant classification committee. We thank Liying Zhang and Judy Garber for their input to this study. This study included data accessed from kConFab (approved project #21). We wish to thank Heather Thorne, Eveline Niedermayr, Sharon Guo, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study for their contributions to this resource, and the many families who contribute to kConFab. We thank Douglas Easton, Manjeet Bolla, and the Breast Cancer Association Consortium (BCAC) for access to results generated as part of iCOGS. Individual BCAC studies and funders as listed the following publications are

acknowledged for their contributions - Michailidou, K. et al. (2013) "Large-scale genotyping identifies 41 new loci associated with breast cancer risk" and Michailidou, K. et al. (2015) "Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer". El Palmero (Barretos Cancer Hospital) thanks members of the Center of Molecular Diagnosis, Oncogenetics Department and Molecular Oncology Research Center of Barretos Cancer Hospital for their contributions to the study. H. Nevanlinna (Helsinki University Hospital) thanks Salla Ranta for her contribution to the study. Luigi Mori from NICEST (Network of Italian Collaborators to ENIGMA Studies and Trials), wishes to thank Chiara Barisani, who is supported by Fondazione Beretta, for technical advice. Ohio State University: The research of A Toland was supported by the Ohio State University Comprehensive Cancer Center. Leigha Senter, Kevin Sweet, Caroline Craven, Julia Cooper, and Michelle O'Connor were instrumental in accrual of study participants, ascertainment of medical records and database management. S. Gutiérrez-Enríquez and Orland Diez (Vall d'Hebron Institute of Oncology) thanks the Cellex Foundation for providing research facilities and equipment.

FUNDING

kConFab and kConFab Clinical Follow Up Study: National Breast Cancer Foundation (Australia), National Health and Medical Research Council (NHMRC), Queensland Cancer Fund, Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, Cancer Foundation of Western Australia, and Cancer Australia.

BCAC and iCOGS: Cancer Research UK (grant numbers C1287/A16563, C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the European Unions Horizon 2020 Research and Innovation Programme (grant numbers 634935 and 633784 for BRIDGES and B-CAST respectively), the European Communitys Seventh Framework Programme under grant agreement no. 223175 (HEALTHF2-2009-223175) (COGS), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065-01 (DRIVE), and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), and the Canadian Institutes of Health Research CIHR) for the CIHR Team in Familial Risks of Breast Cancer (grant PSR-SIIRI-701).

QIMR Berghofer Medical Research Institute: MT Parsons is supported by a grant from Newcastle University, UK E Tudini was supported by a grant from the National Health and Medical Research Council (NHMRC, ID1104808). AB Spurdle is supported by NMHRC Senior Research Fellowship ID 1061778.

Barretos Cancer Hospital: The research of El Palmero was supported by Barretos Cancer Hospital, FINEP - CT-INFRA (02/2010). El Palmero and RM Reis receive a National Council of Technological and Scientific Development (CNPq) scholarship.

Dutch/Belgian Consortium: The work of MPG Vreeswijk was financially supported by the Dutch Cancer Society KWF (UL2012-5649 and KWF/Pink Ribbon-11704). SMoghadasani was

supported by the Netherlands Organization for Scientific Research (NWO), research program Mosaic (Grant 017.008.022) and Van de Kampfonds from Leiden University Medical Centre (Grant 30.925).

French UNICANCER Genetic Group (<http://www.unicancer.fr/recherche/les-groupes-recherche/groupe-genetique-et-cancer-ggc>): S. M. Caputo is supported by the French National Institute of Cancer for the curation of the *BRCA1/BRCA2/PALB2* variant database. Astra Zeneca contributes financially to the COVAR study.

Fundación Pública Galega Medicina Xenómica: A. Vega is supported by the Spanish Health Research Foundation, Instituto de Salud Carlos III (ISCIII), partially supported by FEDER funds through Research Activity Intensification Program (contract grant numbers: INT15/00070, INT16/00154, and INT17/00133), and through Centro de Investigación Biomédica en Red de Enfermedades Raras CIBERER (ACCI 2016: ER17P1AC7112/2018); the Autonomous Government of Galicia (Consolidation and structuring program: IN607B), and by the Fundación Mutua Madrileña (call 2018).

German Consortium for Hereditary Breast and Ovarian Cancer: GC-HBOC is funded by the German Cancer Aid (#110837, #70111850; coordinator: RK. Schmutzler). L Wiesmuller received PhD fellowships from the International Graduate School in Molecular Medicine Ulm University.

Hospital Clínico San Carlos: M de la Hoya is supported by the European Union's Horizon 2020 Research and Innovation Program under grant agreement No 634935, and Spanish Instituto de Salud Carlos III (ISCIII) grant PI15/00059, an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds.

Helsinki University Hospital: The work of H Nevanlinna was supported by the Helsinki University Hospital Research Fund.

Huntsman Cancer Institute, University of Utah: Sean Tavtigian acknowledges support from the National Institutes of Health (CA128978 and CA121245).

ICCon Partnership: ICCon acknowledges input from Miriam Fine, Melissa Monnik, Rachel Austin, Letitia Thrupp, Chris Michael-Lovatt and Gillian Mitchell towards ICCon co-ordination, data collection and curation. The ICCon Partnership is funded by the Cancer Council New South Wales Strategic Research Partnership (STREP) scheme.

Institut Català d'Oncologia: The work of C Lazaro is supported by the Carlos III National Health. The Institut Català d'Oncologia is funded by FEDER funds - a way to build Europe - (PI16/00563 and CIBERONC), the Government of Catalonia (Pla estratègic de recerca i innovació en salut [PERIS_MedPerCan and URDCat projects], 2017SGR1282 and 2017SGR496), and the Scientific Foundation Asociación Española Contra el Cáncer.

Mayo Clinic: The research of F Couch was supported by NIH Specialized Program of Research Excellence (SPORE) in breast cancer (P50 CA1162091), NIH grants CA116167 and CA192393, and the Breast Cancer Research Foundation.

Moffit Cancer Centre: A Monteiro acknowledges support from the NIH (CA116167).

New Zealand Familial Breast Cancer Study: L Walker was supported by the Rutherford Discovery Fellowship (Royal Society

of New Zealand). V Lattimore was supported by the Breast Cancer Foundation of New Zealand Belinda Scott Clinical Fellowship.

NICEST (Network of Italian Collaborators to ENIGMA Studies and Trials): NICEST is partially supported by funds from the Italian Association of Cancer Research (AIRC, Individual grant 15547, to P. Radice).

Ohio State University: The research of A Toland was supported by the Ohio State University Comprehensive Cancer Center.

Pisa University Hospital-SOD Genetica Molecolare: Maria A Caligo is supported by a grant from Fondazione Pisa (Grant "Clinical characterization of BRCA 1/2 Missense variants for evaluation of Breast cancer Risk", 2018–2020).

University of Manchester: DGR Evans and ER Woodward are funded by the NIHR Manchester Biomedical Research Centre (IS-BRC-1215–20007), and ER Woodward is supported by the Cancer Research CRUK Catalyst Award, CanGene-CanVar (C61296/A27223).

Vall d'Hebron Institute of Oncology (VHIO): This study was supported by Spanish Instituto de Salud Carlos III (ISCIII) funding, an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (FIS PI15/00355 to O. Diez, FIS PI13/01711 and FIS PI16/01218 to S. Gutiérrez-Enríquez). S. Gutiérrez-Enríquez is supported by the Miguel Servet Program from ISCIII (CPII16/00034).

CONFLICT OF INTERESTS

The following authors declare conflicts as stated below.

Sandrine M. Caputo: Astra Zeneca contributes financially to the COVAR study.

Laura Cortesi: Astra Zeneca (honoraria), Pfizer (honoraria and advisory role), Amgen (advisory role), and Novartis (advisory role).

Fergus Couch: Steering committee and diagnostics committee for the Astra Zeneca LUCY study.

Anne-Marie Gerdes: February 2016, advisory Board meeting about BRCA1/2 testing in ovarian cancer, sponsored by Astra Zeneca.

Paolo Radice: Scientific coordinator of a course on the classification of BRCA gene allele variants sponsored by Astra Zeneca (Milan, June 2018).

Angela Toss: Lilly (advisory role), Roche (advisory role).

Lisa Wiesmuller is an inventor of a patent on a test system for determining genotoxicities, which is owned by LW.

Ana Vega: October 2015, advisory Board meeting about BRCA1/2 testing in ovarian cancer, sponsored by Astra Zeneca.

All other authors declare that they have no conflict of interests.

ORCID

Michael T. Parsons  <http://orcid.org/0000-0003-3242-8477>

Miguel de la Hoya  <http://orcid.org/0000-0002-8113-1410>

Orland Diez  <https://orcid.org/0000-0001-7339-0570>

Diana M. Eccles  <http://orcid.org/0000-0002-9935-3169>

Sara Gutiérrez-Enríquez  <https://orcid.org/0000-0002-1711-6101>

Rachel Susman  <http://orcid.org/0000-0002-3682-0620>

Sean V. Tavtigian  <http://orcid.org/0000-0002-7543-8221>

Amanda E. Toland  <http://orcid.org/0000-0002-0271-1792>

Angela Toss  <http://orcid.org/0000-0002-1854-6701>

Ana Vega  <http://orcid.org/0000-0002-7416-5137>

Maaïke P. G. Vreeswijk  <http://orcid.org/0000-0003-4068-9271>

Emma R. Woodward  <http://orcid.org/0000-0002-6297-2855>

Paolo Radice  <http://orcid.org/0000-0001-6298-4111>

Amanda B. Spurdle  <http://orcid.org/0000-0003-1337-7897>

REFERENCES

- Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., ... Easton, D. F. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. *American Journal of Human Genetics*, 72(5), 1117–1130.
- Antoniou, A. C., Cunningham, A. P., Peto, J., Evans, D. G., Lalloo, F., Narod, S. A., ... Southey, M. C. (2008). The BOADICEA model of genetic susceptibility to breast and ovarian cancers: Updates and extensions. *British Journal of Cancer*, 98(8), 1457–1466.
- Bouwman, P., van der Gulden, H., van der Heijden, I., Drost, R., Klijn, C. N., Prasetyanti, P., ... Hogervorst, F. B. (2013). A high-throughput functional complementation assay for classification of BRCA1 missense variants. *Cancer Discovery*, 3(10), 1142–1155.
- Breast Cancer Linkage C. (1999). Cancer risks in BRCA2 mutation carriers. *Journal of the National Cancer Institute*, 91(15), 1310–1316.
- Cline, M. S., Babbi, G., Casadio, R., Katsonis, P., Lai, C., Lichtarge, O., ..., O'Conner, R. Manuscript submitted for publication. Assessment of blind predictions of the clinical significance of BRCA variants. *Human Mutation*.
- Coffee, B., Cox, H. C., Kidd, J., Sizemore, S., Brown, K., Manley, S., & Mancini-DiNardo, D. (2017). Detection of somatic variants in peripheral blood lymphocytes using a next generation sequencing multigene pan cancer panel. *Cancer Genetics*, 211, 5–8.
- de la Hoya, M., Soukariéh, O., Lopez-Perolio, I., Vega, A., Walker, L. C., van der Hoven, Y., ... Wijnen, J. (2016). Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. *Human Molecular Genetics*, 25(11), 2256–2268.
- Easton, D. F., Deffenbaugh, A. M., Pruss, D., Frye, C., Wenstrup, R. J., Allen-Brady, K., ... Couch, F. J. (2007). A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. *American Journal of Human Genetics*, 81(5), 873–883.
- Farrugia, D. J., Agarwal, M. K., Pankratz, V. S., Deffenbaugh, A. M., Pruss, D., Frye, C., ... Tavtigian, S. V. (2008). Functional assays for classification of BRCA2 variants of uncertain significance. *Cancer Research*, 68(9), 3523–3531.
- Fernandes, V. C., Golubeva, V. A., Di Pietro, G., Shields, C., Amankwah, K., Nepomuceno, T. C., ... Gomes, T. T. (2019). Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation. *Journal of Biological Chemistry*, 294(15), 5980–5992.
- Findlay, G. M., Daza, R. M., Martin, B., Zhang, M. D., Leith, A. P., Gasperini, M., ... Shendure, J. (2018). Accurate classification of BRCA1 variants with saturation genome editing. *Nature*, 562(7726), 217–222.
- Ford, D., Easton, D. F., Bishop, D. T., Narod, S. A., & Goldgar, D. E. (1994). Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. *Lancet*, 343(8899), 692–695.

- Goldgar, D. E., Easton, D. F., Byrnes, G. B., Spurdle, A. B., Iversen, E. S., & Greenblatt, M. S. (2008). Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. *Human Mutation*, 29(11), 1265–1272.
- Goldgar, D. E., Easton, D. F., Deffenbaugh, A. M., Monteiro, A. N., Tavtigian, S. V., & Couch, F. J. (2004). Breast Cancer Information Core Steering C. (2004). Integrated evaluation of DNA sequence variants of unknown clinical significance: Application to BRCA1 and BRCA2. *American Journal of Human Genetics*, 75(4), 535–544.
- Guidugli, L., Carreira, A., Caputo, S. M., Ehlen, A., Galli, A., Monteiro, A. N., ... Vreeswijk, M. P. (2014). Functional assays for analysis of variants of uncertain significance in BRCA2. *Human Mutation*, 35(2), 151–164.
- Hart, S. N., Hoskin, T., Shimelis, H., Moore, R. M., Feng, B., Thomas, A., ... Iversen, E. (2019). Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models. *Genetics in Medicine*, 21(1), 71–80.
- Houdayer, C., Caux-Moncoutier, V., Krieger, S., Barrois, M., Bonnet, F., Bourdon, V., ... Gaildrat, P. (2012). Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. *Human Mutation*, 33(8), 1228–1238.
- Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K. A., Mooij, T. M., Roos-Blom, M. J., ... Andriew, N. (2017). Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. *Journal of the American Medical Association (Chicago, IL)*, 317(23), 2402–2416.
- Lee, K., Krempely, K., Roberts, M. E., Anderson, M. J., Carneiro, F., Chao, E., ... Huntsman, D. (2018). Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants. *Human Mutation*, 39(11), 1553–1568.
- Lee, M. S., Green, R., Marsillac, S. M., Coquelle, N., Williams, R. S., Yeung, T., ... Monteiro, A. N. (2010). Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. *Cancer Research*, 70(12), 4880–4890.
- Lindor, N. M., Guidugli, L., Wang, X., Vallee, M. P., Monteiro, A. N., Tavtigian, S., ... Couch, F. J. (2012). A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). *Human Mutation*, 33(1), 8–21.
- Lovelock, P. K., Spurdle, A. B., Mok, M. T., Farrugia, D. J., Lakhani, S. R., Healey, S., ... Couch, F. J. (2007). Identification of BRCA1 missense substitutions that confer partial functional activity: Potential moderate risk variants? *Breast Cancer Research*, 9(6), R82.
- Maxwell, K. N., Domchek, S. M., Nathanson, K. L., & Robson, M. E. (2016). Population frequency of germline BRCA1/2 mutations. *Journal of Clinical Oncology*, 34(34), 4183–4185.
- Mesman, R. L. S., Calleja, F., Hendriks, G., Morolli, B., Misovic, B., Devilee, P., ... Vreeswijk, M. P. G. (2019). The functional impact of variants of uncertain significance in BRCA2. *Genetics in Medicine*, 21, 293–302.
- Mester, J. L., Ghosh, R., Pesaran, T., Huether, R., Karam, R., Hruska, K. S., ... Barnholtz-Sloan, J. (2018). Gene-specific criteria for PTEN variant curation: Recommendations from the ClinGen PTEN expert panel. *Human Mutation*, 39(11), 1581–1592.
- Michailidou, K., Hall, P., Gonzalez-Neira, A., Ghoussaini, M., Dennis, J., Milne, R. L., ... Bolla, M. K. (2013). Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nature Genetics*, 45(4), 353–361.361e1-2
- Millot, G. A., Carvalho, M. A., Caputo, S. M., Vreeswijk, M. P., Brown, M. A., Webb, M., ... Galli, A. (2012). A guide for functional analysis of BRCA1 variants of uncertain significance. *Human Mutation*, 33(11), 1526–1537.
- Moran, A., O'Hara, C., Khan, S., Shack, L., Woodward, E., Maher, E. R., ... Evans, D. G. (2012). Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. *Familial Cancer*, 11(2), 235–242.
- Petalot, A., Dardillac, E., Jacquet, E., Nhiri, N., Guirouilh-Barbat, J., Julien, P., ... Schnell, J. A. (2019). Combining homologous recombination and phosphopeptide-binding data to predict the impact of BRCA1 BRCT variants on cancer risk. *Molecular Cancer Research*, 17(1), 54–69.
- Pilie, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019). State-of-the-art strategies for targeting the DNA damage response in cancer. *Nature Reviews Clinical Oncology*, 16(2), 81–104.
- Plon, S. E., Eccles, D. M., Easton, D., Foulkes, W. D., Genuardi, M., Greenblatt, M. S., ... Tavtigian, S. V. (2008). Sequence variant classification and reporting: Recommendations for improving the interpretation of cancer susceptibility genetic test results. *Human Mutation*, 29(11), 1282–1291.
- Rehm, H. L., Berg, J. S., Brooks, L. D., Bustamante, C. D., Evans, J. P., Landrum, M. J., ... Nussbaum, R. L. (2015). ClinGen—the clinical genome resource. *New England Journal of Medicine*, 372(23), 2235–2242.
- Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., ... Spector, E. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in Medicine*, 17(5), 405–424.
- Rivera-Munoz, E. A., Milko, L. V., Harrison, S. M., Azzariti, D. R., Kurtz, C. L., Lee, K., ... Craigen, W. (2018). ClinGen variant curation expert panel experiences and standardized processes for disease and gene-level specification of the ACMG/AMP guidelines for sequence variant interpretation. *Human Mutation*, 39(11), 1614–1622.
- Rouleau, E., Lefol, C., Moncoutier, V., Castera, L., Houdayer, C., Caputo, S., ... Stoppa-Lyonnet, D. (2010). A missense variant within BRCA1 exon 23 causing exon skipping. *Cancer Genetics and Cytogenetics*, 202(2), 144–146.
- Spurdle, A. B., Couch, F. J., Parsons, M. T., McGuffog, L., Barrowdale, D., Bolla, M. K., ... Wappenschmidt, B. (2014). Refined histopathological predictors of BRCA1 and BRCA2 mutation status: A large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. *Breast Cancer Research*, 16(6), 3419.
- Spurdle, A. B., Greville-Heygate, S., Antoniou, A. C., Brown, M., Burke, L., de la Hoya, M., ... Monteiro, A. N. (2019). Towards controlled terminology for reporting germline cancer susceptibility variants: An ENIGMA report. *Journal of Medical Genetics*, 56(6), 347–357.
- Spurdle, A. B., Healey, S., Devereau, A., Hogervorst, F. B., Monteiro, A. N., Nathanson, K. L., ... Wappenschmidt, B. (2012). ENIGMA—evidence-based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. *Human Mutation*, 33(1), 2–7.
- Starita, L. M., Islam, M. M., Banerjee, T., Adamovich, A. I., Gullingsrud, J., Fields, S., ... Parvin, J. D. (2018). A multiplex homology-directed DNA repair assay reveals the impact of more than 1,000 BRCA1 missense substitution variants on protein function. *American Journal of Human Genetics*, 103(4), 498–508.
- Tavtigian, S. V., Byrnes, G. B., Goldgar, D. E., & Thomas, A. (2008). Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications. *Human Mutation*, 29(11), 1342–1354.
- Tavtigian, S. V., Greenblatt, M. S., Harrison, S. M., Nussbaum, R. L., Prabhu, S. A., Boucher, K. M., & Biesecker, L. G., ClinGen Sequence Variant Interpretation Working G. (2018). Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. *Genetics in Medicine*, 20(9), 1054–1060.
- Thompson, B. A., Spurdle, A. B., Plazzer, J. P., Greenblatt, M. S., Akagi, K., Al-Mulla, F., ... den Dunnen, J. T. (2014). Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. *Nature Genetics*, 46(2), 107–115.

- Thompson, D., Easton, D. F., & Breast Cancer Linkage C (2002). Cancer Incidence in BRCA1 mutation carriers. *Journal of the National Cancer Institute*, 94(18), 1358–1365.
- Thompson, D., Easton, D. F., & Goldgar, D. E. (2003). A full-likelihood method for the evaluation of causality of sequence variants from family data. *American Journal of Human Genetics*, 73(3), 652–655.
- Tuffaha, H. W., Mitchell, A., Ward, R. L., Connelly, L., Butler, J. R. G., Norris, S., & Scuffham, P. A. (2018). Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers. *Genetics in Medicine*, 20(9), 985–994.
- Vallee, M. P., Di Sera, T. L., Nix, D. A., Paquette, A. M., Parsons, M. T., Bell, R., ... Spurdle, A. B. (2016). Adding in silico assessment of potential splice aberration to the integrated evaluation of BRCA gene unclassified variants. *Human Mutation*, 37(7), 627–639.
- Walker, L. C., Whiley, P. J., Houdayer, C., Hansen, T. V., Vega, A., Santamarina, M., ... Lafferty, A. (2013). Evaluation of a 5-tier scheme proposed for classification of sequence variants using bioinformatic and splicing assay data: Inter-reviewer variability and promotion of minimum reporting guidelines. *Human Mutation*, 34(10), 1424–1431.
- Whiffin, N., Minikel, E., Walsh, R., O'Donnell-Luria, A. H., Karczewski, K., Ing, A. Y., ... MacArthur, D. (2017). Using high-resolution variant frequencies to empower clinical genome interpretation. *Genetics in Medicine*, 19(10), 1151–1158.
- Whiley, P. J., Guidugli, L., Walker, L. C., Healey, S., Thompson, B. A., Lakhani, S. R., ... Goldgar, D. E. (2011). Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary. *Human Mutation*, 32(6), 678–687.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Parsons MT, Tudini E, Li H, et al. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. *Human Mutation*. 2019;40:1557–1578. <https://doi.org/10.1002/humu.23818>